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Executive summary 
Background 
Transforming Care, the Government report into the events at Winterbourne View, noted 
‘deep concerns’ about the over-use of antipsychotic and antidepressant medicines in 
people with learning disabilities and/or autism.1 These concerns related to the extent to 
which these drugs are used outside licensed indications with the aim of managing 
problem behaviour. This study was designed to identify how many people in these 
groups are treated with these types of drugs, how the drugs are used and how much of 
this use is for licensed clinical indications.  
 
The scope was widened to include anxiolytics, hypnotics, anticonvulsants and, to some 
extent, mood stabilisers as studies indicate that these have all been considered 
relevant to management of behaviour.2 The study aimed to provide information about 
people with learning disabilities or autism generally, not just those in touch with 
specialist mental health services. As such, we utilised general practice records from the 
Clinical Practice Research Datalink primary care database (CPRD GOLD). This is a 
well-established system that collects comprehensive anonymised clinical data from a 
large number of general practices throughout the UK for research studies.    
 
Methods 
Using the anonymised database, we searched for clinical records of patients living in 
England and registered with GPs between April 2009 and March 2012 who were 
identified as having either learning disabilities or autism. Excluding periods when this 
group were hospitalised we noted periods during which they were exposed to any 
drugs in the British National Formulary (BNF) sections 4.1 (hypnotics and anxiolytics), 
4.2 (drugs used in psychoses and related disorders), 4.3 (antidepressant drugs) and 
4.8 (antiepileptic drugs). We recorded duration of exposure, combinations of drugs 
within and between BNF sections, dosages and the recording of Read coded 
diagnoses which are recognised indications for the medications. Our analysis focussed 
mainly on hypnotics (4.1.1), anxiolytics (4.1.2), antipsychotic drugs (4.2.1) 
antidepressants (4.3) and antiepileptics (4.8).    
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Findings 
The numbers of relevant patients identified (17,887 people with learning disabilities and 
an additional 11,136 with autism) suggested that the database covers about 7.8% of 
the English population. A substantial number of people with learning disabilities was 
identified in each of the predefined age categories, whilst those identified as having 
autism alone were predominantly (76.5%) aged under 18. The proportion of those 
identified as having learning disabilities who were also identified as having autism was 
much smaller than expected. 
 
People with learning disabilities:  
Patients were exposed to one or more of the drugs we studied on 41.3% of person 
days for adults and 14.7% for children and young people. Excluding antiepileptics, the 
figures were 29.5% of adult- and 6.8% of children and young people’s person-time. 
Antipsychotic drugs were being prescribed on 17.0% of adult and 2.4% of children and 
young people’s person-days, drugs used in mania and hypomania on 7.1% and 0.3% 
respectively, antidepressants on 16.9% and 1.2%, anxiolytics on 4.2% and 0.6% and 
antiepileptic drugs on 22.9% and 10.2%. Hypnotics were the only group of drugs we 
studied for which a higher proportion of children and young people’s time was exposed 
(children and young people 4.1% of person-days vs adults 2.7%). For most groups of 
drugs, exposure rates rose through adult life.  The rate of prescribing antipsychotics in 
people aged 65 and over was 3.3 times the rate in those aged 18 to 24; corresponding 
multiples were 1.8 for hypnotics, 2.9 for anxiolytics, 2.5 for drugs used in mania and 
hypomania and 2.7 for antidepressants. The multiple was much less (1.3) for 
antiepileptics.  
 
People with autism:  
For people with autism but not learning disabilities, the rates we can report for children 
were based on large numbers and therefore probably reflect the experience of people 
with autism in the population reasonably well. Adult rates were based on much smaller 
numbers of individuals. Interpretting adult rates therefore requires some allowance for 
the issue of the effective selection critieria leading to those individuals having their 
autism identified and recorded by their GP.  It is likely that this would be a particularly 
disabled group, not representative of the generality of adults with autism in the 
population. Among those aged under 18, 1.5% of person days were exposed to 
prescribing of antipsychotics, 0.2% drugs for the management of mania and 
hypomania, 1.1% antidepressants, 3.2% hypnotics, 0.1% anxiolytics and 2.0% anti-
epileptics. Corresponding rates for adults with autism were: antipsychotics 8.2%, drugs 
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for the management of mania and hypomania 3.5%, antidepressants 17.0%, hypnotics 
2.1%, anxiolytics 1.8% and anti-epileptics 6.9%. 
 
Patterns of prescribing:  
A large proportion (90% or more) of the prescribing of drugs in most of the BNF 
sections and sub-sections we studied was not short term, in the sense that 
prescriptions were followed by at least one repeat prescription. The only exceptions to 
this appeared to be anxiolytics, for acults with autism, hypnotics. However even for 
these groups the majority of periods of prescribing involved more than a single 
prescription.   
 
Prescribing of more than one drug within BNF a sub-section was seen for adults with 
learning disabilities in 22.5% of prescriptions for antipsychotic drugs, 10.8% for 
antidepressants and 43.3% for antiepileptics. Simultaneous prescribing of drugs from 
more than one of the five BNF (sub)-sections we studied in more detail was also 
common.  Two in five adults (39.9%) and 17.6% of all children and young people with 
learning disabilities who were receiving any of the drugs were receiving drugs from two 
or more groups. Corresponding proportions for people with autism but not learning 
disabilities were 30.3% for adults and 13.6% for children and young people. 
 
Relatively little prescribing was reported to be at doses above BNF recommended 
limits. For antipsychotics this applied to 5.5% of prescriptions for adults with learning 
disabilities and 5.6% for adults with autism, and for both hypnotics and anxiolytics to 
2.4% of prescriptions for adults with learning disabilities. High dose rates were seen for 
roughly double these proportions in the youngest adult age group. In all other cases 
high doses were recorded in fewer than 2% of prescriptions. However in 27.1% of 
prescriptions overall, the recording of the dose did not allow this analysis.  
 
The proportions of patients for whom Read codes for licensed indications were 
recorded for the drugs prescribed varied and was difficult to interpret. Amongst adults 
with learning disabilities, potentially relevant indications were recorded in the notes of 
41.9% of those prescribed antipsychotics, 68.2% prescribed antidepressants, 44.1% 
prescribed hypnotics and 53.6% prescribed anxiolytics.  A much higher proportion of 
those receiving anti-epileptics (90.7%) had records of relevant indications. These 
patterns were broadly reflected for other groups except that relevant indications were 
less often recorded for children and young people in relation to hypnotics, anxiolytics 
and antipsychotics. 
 
Comparison with epidemiological studies of mental illness in adults with learning 
disabilities suggests that 13% of the population (roughly 23,800 people) are being 
prescribed antipsychotics in the absence of a psychotic illness, and 10% 
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antidepressants in the absence of an affective illness (roughly 19,500 people).  
Allowing for overlap, which is common, we estimate that between 30,000 and 35,000 
adults with a learning disability in England are taking one or both of these types of drug 
in the absence of the conditions for which they are indicated.  Prescribing of 
antipsychotics and antidepressants to children and young people is much less 
common. It is less clear that rates for this group are disproportionate to the same 
extent. 
 
Discussion 
The data source we used is well established and widely studied. There is no reason to 
doubt that the pattern of prescribing recorded is a good reflection of prescribing by GPs 
for the patients concerned. However, drugs prescribed by secondary care staff, or in in-
patient settings were excluded from this study and we have no way of telling to what 
extent the patients took the drugs prescribed.    
 
Analysing the extent to which people prescribed medications had records of relevant 
conditions proved difficult. In our judgement we are likely to have over-estimated the 
proportions of people prescribed drugs who actually had relevant indications.  
 
The study shows antipsychotic and antidepressant drugs are being prescribed for 
people with learning disabilities in England in the absence of recording of the conditions 
for which they are known to be effective. This is in line with the results of previous 
studies. The two contributions this study makes are first that it establishes the scale 
and patterns of prescribing and second that it demonstrates that the database we used 
documents it well. The approach used in this paper, with reasonably straightforward 
enhancements, would thus provide a useful method of monitoring the progress of 
attempts to tackle this problem.    
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Introduction 
This study examined the prescribing of drugs acting on the central nervous system to 
people with learning disabilities or autism by general practitioners (GPs) in England. It 
forms part of the wider review of the prescribing of antipsychotic and antidepressant 
medicines for people with challenging behaviour undertaken as a result of the 
investigations into care for this group following the exposure of the events at 
Winterbourne View hospital 
 
The authors of the government’s final report into Winterbourne View noted that they had 
heard ‘deep concerns about over-use of antipsychotic and antidepressant medicines’.[1 
- paragraph 7.31] The action arising from this observation was that a review would be 
commissioned of the prescribing of antipsychotic and antidepressant medications. It is 
not practical to encompass all prescribing for people with learning disabilities or autism 
in a single study design. This study was designed to look at the experience of the 
largest natural sub-group – those people who are currently not in hospital and who, for 
the most part, may be assumed to be receiving most or all of the drugs they take on the 
basis of prescriptions issued by their GP.   
 
The study focussed on the use of drugs in four of the sections of chapter 4 of the British 
National Formulary (BNF). Antipsychotic drugs (BNF section 4.2.1 and 4.2.2) and 
antidepressant drugs (4.3) were naturally included.  However, published literature 
indicates a wider range of drugs is used for behaviour management in this group of 
people.3,4 Accordingly we widened the range of drugs studied to include hypnotics 
(4.1.1), anxiolytics (section 4.1.2), the rest of the section covering drugs used in 
psychoses and related disorders (4.2) and antiepileptic drugs (4.8). The aim was to 
document the extent and patterns of prescribing of these drugs for people with learning 
disabilities and/or autism and to explore how much of this related to recorded diagnoses 
of licenced indications for the drugs.  
 
The study was descriptive, using data from a major UK general practice research 
dataset, the Clinical Practice Research Datalink primary care database (CPRD GOLD). 
This is a large anonymised data source which draws from clinical case notes made by 
GPs in participating practices throughout the UK. 
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Background 
i. Use of medication in the management of behaviour in people with learning disabilities 
and/or autism 
Drugs in the categories studied (anxiolytics, hypnotics, drugs used in the management 
of psychosis and related disorders, antidepressants and antiepileptics) all have 
appropriate and licensed uses in the treatment of the conditions for which their category 
names indicate they are primarily intended. Some people with learning disabilities 
and/or autism suffer these conditions; in the cases of psychotic disorders and epilepsy, 
larger proportions than the general population.5 However, these drugs are also widely 
used in people with learning disabilities, and also at least in young people with autism, .  
in the hope that they will assist in the management of behaviour carers find 
problematic.6 This usage is mostly unlicensed and in most cases substantial evidence 
of its efficacy is largely lacking.3,7,8  
 
The specific exception to this is in children with autism. Two well-designed randomised 
trials have recently demonstrated that risperidone can be effective in treating behaviour 
disorders not responsive to non-pharmacological treatment approaches in this group.9,10 
The group of drugs most strongly associated with longer term use for behaviour 
management is the antipsychotics. Many of these have sedative properties, at least 
initially. Some are licensed for rapid tranquilisation to manage acute violent disturbance, 
some for management of severe anxiety as well as psychosis and two, in limited 
situations, for management of behaviour. The evidence that these two, (haloperidol and 
risperidone) are effective beyond immediate sedation in the management of aggressive 
behaviour, one of the most commonly reported purposes for their use in people with 
intellectual disability, has been called into question by a major study by Tyrer et al.11 In 
a randomised controlled trial, these authors failed to find any significant benefit of either 
for this purpose greater than placebo. Studies of progressive withdrawal of antipsychotic 
medication in people with learning disability where this had been prescribed for 
management of behavioural problems for a year or more have shown that in half or 
more cases, full or partial withdrawn of the drugs can be achieved with no deterioration 
in behaviour and improvements in general activity levels.12,13  
 
Assessing the appropriateness of using psychotropic medications in people with 
learning disabilities is often far from easy. In some cases difficult behaviours can arise 
as a symptom of underlying psychiatric illness, or some types of epilepsy. In these 
circumstances the use of appropriate drugs to treat the underlying condition may well be 
beneficial. However, in the absence of mental illness or epilepsy, they have little 
relevant effect beyond, in some cases, sedation and carry well known risks of side 
effects. But establishing clearly whether a person has a major psychiatric illness is 
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particularly difficult when their capacity to communicate is limited. This means that 
treatment plans are often initiated in a situation of some diagnostic uncertainty. The 
approach recommended by a consensus group of the Royal College of Psychiatrists 
and the British Psychological Society is a detailed functional analysis of the behaviour 
followed by a variety of mainly behavioural interventions. If psychotropic medication 
forms part of the plan, it should be targeted at a specific psychiatric illness or symptom. 
Frequent review with fine tailoring of doses and withdrawal of drugs where they are 
ineffective or no longer needed is an important component.14   
 
Deb and his colleagues proposed guidelines for prescribing of psychotropic medications 
for the management of problem behaviours.15,16 Noting the limited evidence of their 
effectiveness and the potential for adverse effects, they recognised nevertheless that 
these drugs were widely used. In this context they set out to establish which drugs 
psychiatrists considered most appropriate and to propose principles for good practice. 
In addition to the questions prior to prescribing, they considered issues of duration, 
review and withdrawal of medication, use of high drug dosages and multiple drugs. 
They advised that dosages should be as low as possible consistent with response and 
that with the exception of anti-epileptics, use of multiple drugs, particularly from the 
same class of psycho-active medication should be avoided. 
 
Paton and her colleagues at the Prescribing Observatory for Mental Health in the 
Research Unit of the Royal College of Psychiatrists undertook a large scale national 
audit of the use of antipsychotic medication for people with learning disabilities under 
the care of UK mental health services.17 Their study was intended to explore the clinical 
rationale for prescribing and to see how far it was consistent with current good practice 
guidelines including those described above.14 The study only explored the use of 
antipsychotics and the sampling approach used could not be relied on to produce a 
representative picture of current practice. Respondents reported on the clinical 
indications for which 2319 patients with learning disabilities were being prescribed 
antipsychotics and some associated clinical aspects of their care. Eighty-eight percent 
had a diagnosable mental illness of some type, 42% a psychosis. Amongst both these, 
and the 12% who did not, a range of behavioural issues including (most prominently) 
overt aggression, threatening behaviour and self-harm were given as clinical indications 
for the use of these drugs. Eighty-five percent of patients had been receiving treatment 
for more than a year. Monitoring of important side effects was seriously deficient. 
However the design of the study did not allow conclusions about the overall prevalence 
of use of antipsychotics (in the presence or absence of evidence of psychotic illness), or 
the extent to which this varied around the country. 
 
There has not previously been a large scale population-based study of the extent of use 
of psychotropics in people with learning disabilities in England. Several authors have 
studied the scale of off-label prescribing in local services. 18–20 Cooper recorded the 
prevalence of use of psychotropic medication in her 2007 population based study of all 
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adults with intellectual disabilities in Glasgow.21  She found that 49.5% were taking 
some form of psychotropic drug, with 23.2% taking an antipsychotic (compared with 
4.4% who had psychotic illnesses). She also reported that high proportions were taking 
antidepressants, anxiolytics and mood stabilisers, although in this secondary report, 
these rates were not detailed numerically. Murray and her colleagues recently reported 
a population level study of psychotropic medication prescribed to children and young 
people (aged under 25) with autism in the UK, using a different general practice 
research database.6 They reported a large rise in the identified prevalence of autism 
between 1992 and 2008 (from 0.01% to 0.50%, with psychotropic drugs being 
prescribed to 29% of these. The most widely prescribed drugs in the groups they 
studied were sleep medication (9.7%), psychostimulants (7.9%) and antipsychotics 
(7.3%). The rate of use of sleep medication and psychostimulants amongst those 
identified as having autism showed a three to four fold rise in the decade from 1999 to 
2008, use of antipsychotics remained steady.   
 
ii Locations of clinical care  
The overall scope for consideration adopted by the Transforming Care programme was 
care for people who show challenging behaviour associated with learning disability or 
autism (para 1.1). Whilst the events at Winterbourne View occurred in a hospital, the 
concerns that fall within this scope cover a much wider range of care settings.   
Psychotropic drugs are used as part of management programmes for individuals across 
the full range of types of residential accommodation. There is currently little evidence 
about whether drugs are used more or less sparingly in different types of setting. One 
study identified more extensive use of medication as an approach to the management 
of challenging behaviour in registered residential care homes than in larger, campus-
based units.22  Thus an appropriate scope for a review would be to identify patterns of 
care as far as possible, in all types of residential setting.  
 
For this reason, whilst hospital prescribing is important (and the subject of an 
accompanying piece of work1) it was also important for the Transforming Care 
programme to study care provided outside hospital. The most practical approach to this 
was to study GP prescribing. For most people who are not in hospital, the GP has a 
central role in co-ordinating medical aspects of care including the prescribing of 
medication. GPs commonly refer patients to specialists for assessments and 
recommendations about treatment plans, but generally they oversee the week-to-week 
management of long term conditions and undertake any long term prescribing 
themselves. This applies to patients living in private households, supported living 
environments and residential care homes.  
                                            
 
1
 www.nhsiq.nhs.uk/winterbourne 
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iii The Clinical Practice Research Datalink  
The study was based entirely on analysis of operational clinical notes made by GPs in 
the course of their work. These were available to us in the Clinical Practice Research 
Datalink primary care database (CPRD GOLD). CPRD is a UK NHS observational data 
and interventional research service, jointly funded by the NHS National Institute for 
Health Research (NIHR) and the Medicines and Healthcare Products Regulatory 
Agency (MHRA). It developed from work drawing anonymised data from general 
practice information systems for the purpose of studying the occurrence of rare but 
important drug side-effects. Comprehensive data about the transactions between 
patients and GPs are collected. The nature of the role of the GP in the English health 
service means that this gives a near comprehensive overview of the healthcare 
received by a definable population, albeit with uneven levels of detail.  
 
The database holds comprehensive data about primary care interactions from selected 
GP practices.23 Participating practices have staff training in data recording. Data quality 
and completeness are routinely monitored. Practices have to reach a recording quality 
threshold to be included in an analysis dataset. In the UK, patients are affiliated to a 
practice on a semi-permanent basis. It is relatively uncommon for them to switch 
practices other than as a result of substantial residential moves. Practice data, 
therefore, give a fairly comprehensive view of medical aspects of individuals’ lives over 
a substantial period of time. The CPRD primary care database includes records of 
demographic information, prescription details, clinical events, preventive care provided, 
and specialist referrals. Recent changes have enabled the development of the system 
to allow data derived from general practice records to be linked directly to records 
relating to secondary care from a wide range of healthcare and mortality data sources. 
For this study the most important such linkage was to hospital statistics which show 
periods when patients are in hospital. The system currently collects information on 
approximately 5 million GP patients, although not all of these live in England. We 
estimate the effective population coverage below. 
 
The system is well suited to this study in several ways. Within the population covered, 
individuals with a learning disability are relatively easy to identify. This is because GPs 
maintain registers of them as a requirement under a national quality programme (the 
quality and outcomes framework - QOF) for which they receive incentive payments.24 
As well as providing an incentive, this programme also provides mandatory coding 
details. Further QOF registers cover many of the other diagnoses for which the drugs in 
this study are licensed (depression, psychotic illness and epilepsy), also providing 
effective definitional frameworks for these. As a result of its original purpose, the system 
is designed to give optimal coverage of drug prescribing. It covers GP prescribing of all 
types. Where individuals are hospitalised (and thus the task of prescribing drugs 
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switches temporarily to hospital doctors) this should usually be apparent from linked 
hospital data.2  
 
 
  
                                            
 
2
The exception to this is when people are in NHS funded care in private hospitals. At the time to which the data 
studied relate, private mental hospitals did not report on these in the standard NHS statistical datasets. 
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Aims and objectives 
The study set out to explore four aspects of the use of the four classes of drugs of 
interest (anxiolytics and hypnotics, drugs used in the management of psychosis and 
related disorders, antidepressants and antiepileptics) in patients with learning 
disabilities or autism.  
 
These were: 
1. The overall extent of their use, 
2. Prescribing patterns; specifically the extent to which use was short term or ongoing, 
the extent to which people were being prescribed more than one compound in each of 
the four BNF sections, and whether dosages were within the range recommended by 
the BNF,  
3. The extent to which use of these drugs was associated with recording of recognised 
indications, and  
4. Variations in these patterns between subgroups of patients 
Sources, methods, analysis and presentation 
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Methods 
i. Data sources 
GP prescribing and diagnostic data were obtained from the Clinical Practice Research 
Datalink (CPRD) primary care database. We identified patients with learning disabilities 
using the codes listed in the technical specification of the Quality and Outcomes 
Framework indicator LD01. An NHS Information Centre study showed that a number of 
people who are clearly known to have learning disabilities may not be included in these 
registers.25 Accordingly we supplemented this code list  with codes for diagnoses 
reliably associated with learning disabilities listed in the Learning Disabilities 
Observatory study of mortality.24,26 We identified people with autism from Read codes 
related to the ICD10 diagnoses F840 (childood autism), F841 (atypical autism) and 
F845 (Asperger syndrome).  We used GP practice and patient registration data to 
identify the periods for which they were potentially visible for analysis and data on 
hospital episodes to identify periods for which GP prescribing would not have occurred.  
 
ii. Patient group  
The study used a cohort design. A single cohort of patients defined by having a 
recorded diagnosis of learning disability or autism was identified. Learning disability or 
autism were considered to be persistent conditions, so a diagnosis at any time was 
considered to be relevant to the whole study period.  
 
Patients were available for selection if they met three inclusion criteria. They needed a 
qualifying diagnosis, at least one day of permanent registration with a qualifying practice 
between 1st April 2009 and 31st March 2012, and they needed to be eligible for linkage 
to the inpatient Hospital Episode Statistics (HES) data. ‘Eligibility’ for linkage required 
them to be registered with a practice, in England, that had consented to take part in the 
scheme linking GP to hospital data, and they had to have a valid NHS number recorded 
in their primary care records thereby making linkage possible. Approximately 75% of 
English practices that contribute to CPRD also participate in this scheme. 
 
A study window for each patient was defined as starting at the latest of the study start 
date (1st April 2009), the patient’s current registration date and the up-to-standard date 
of the practice, and finishing with the earliest of the end of the study period (31st March 
2012), end of patient’s registration (if applicable), or the last collection date of the 
practice. Periods when patients were in hospital were excluded from their study window. 
The April 2014 version of the CPRD GOLD database was used. 
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Patients were characterised, by their age at study entry point, gender and diagnosis 
(learning disability (with or without autism), and autism without recorded learning 
disability). These categories were used to stratify most analyses.  
 
 
iii. Drugs and prescribing 
Psychotropic prescribing was defined as at least one GP prescription recorded in the 
CPRD GOLD therapy file for a drug in one of the four selected sections of the BNF 
chapter on drugs affecting the central nervous system. The sections were hypnotics and 
anxiolytics (BNF section 4.1), drugs used in psychosis or related disorders (4.2), 
antidepressant drugs (4.3) and antiepileptic drugs (4.8). For reporting purposes we have 
generally divided drugs in section 4.1 into those considered as hypnotics (4.1.1) and as 
anxiolytics (4.1.2). In section 4.2 we have focussed more on antipsychotic drugs (4.2.1) 
than on drugs used in the control of mania and hypomania (4.2.3). We have mainly 
reported on sections 4.3 and 4.8 as whole groups. There was too little use of 
barbiturates (4.1.3), monoamine oxidase inhibitors (4.3.2) or depot antipsychotics 
(4.2.2) for extensive reporting, although the small number of prescriptions for these 
identified were included in section totals. Appendix tables show figures for all the sub-
sections.     
 
Periods of use of drugs for patients were calculated from the total quantity prescribed 
and available daily dosage information. Durations were rounded up to a minimum of 1 
day, or down to a maximum of 365 days where relevant. Where quantity or dosage 
information was missing a standard prescription length of 28 days was used. A 
subsequent prescription that occurred within the estimated duration of the original 
prescription plus a 56 day “grace period” was considered to be part of the same 
treatment episode. If there was any overlap, treatment episodes were censored at a 
patient’s study start and end dates. Treatment episodes were calculated for each group 
of drugs (based on BNF sections and sub-sections) and the dosage for each treatment 
episode was classified as within or above the maximum BNF-recommended daily 
dosage or missing. These are standard approaches for analysis of prescribing using this 
data source.  
 
iv. Indications for Prescribing 
For each drug compound (and, where appropriate, dose range) a list of approved 
indications was constructed, including, for example, psychotic illness, bipolar 
depression, unipolar depression, anxiety, ADHD and epilepsy. Read code lists for each 
indication were constructed by RW and ambiguous elements of these were reviewed by 
GG, UC and MH. UC and MH are both experienced GPs with special expertise in the 
care of people with learning disabilities. Most relevant indications could reasonably be 
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considered as chronic or likely recurrent conditions. As such, CPRD GOLD clinical and 
referral records were searched for Read codes for recognised indications both before 
and after prescribing events. We did not search text fields. On this basis records of 
indications were categorised as “contemporary” (within 28 days of the start of the 
treatment episode), “prior” (more than 28 days before the start of the treatment 
episode), and “following” (more than 28 days after the start of the treatment episode). 
Where more than one record of an indication was entered, contemporary records were 
chosen in preference to prior records, which were chosen in preference to following 
records. 
 
v. Statistical analysis 
Following an initial description of the patient group involved, the analysis was conducted 
in five main sections:  
 
Exposure 
The extent of prescribing of drugs from each of the BNF sections is reported as the 
proportion of observed person days in which patients were exposed to the drugs. 
Exposure periods were calculated from reported treatment episodes, plus intervening 
‘grace periods’ if applicable (see above). The denominator (observed patient days) was 
the whole of each patient’s registration period omitting hospitalised days. Periods of 
hospitalisation were also excluded from the exposed days even if a prescribing episode 
was unfinished at the time of admission. Confidence intervals for rates were calculated 
using the Wilson method for standard errors of proportions using our own visual basic 
routines for Microsoft Access.27 
 
Variations 
We explored variations between the three study years and between geographic regions 
in England.  
 
Treatment patterns 
For exploration of treatment patterns, each episode of prescribing (essentially each 
prescription) of a drug for a patient was categorised in three ways. It was labelled as 
“acute” or “on-going” on the basis of whether it was directly followed by a subsequent 
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prescription for a drug from the same BNF section or sub-section, as “multiple” or not on 
the basis of whether two or more drug compounds from the BNF section / sub-section 
were prescribed at the same time, and as high-dose or not according to whether the 
prescribed dose exceeded BNF recommended limits. Dose limits for normal use were 
taken from the BNF April 2014 edition. The analysis of prescribing episodes was based 
on prescriptions not people as clearly a patient’s status in respect of these categories 
can change.  
 
Combinations of drugs 
In addition to identifying multiple prescribing within BNF sections we also conducted a 
cross-sectional analysis to identify the proportion of prescribing episodes where a 
patient was simultaneously given drugs from more than one of the sections studied. We 
report on the combinations.  
 
Indications 
The presence of recognised indications for prescribing is also reported for prescribing 
episodes. The counts and proportions of treatment episodes with an approved 
indication, and approved dosage, are presented overall, and to show the timing of 
recording of the indication in relation to the prescription. Each of the BNF drug sections 
considered had a range of recognised indications. We explored all of these 
notwithstanding the fact that some would normally be considered relatively unusual 
reasons for use of the drugs. This rather problematic analysis is described in more 
detail along with the results. 
 
Data management and analysis at the CPRD level was undertaken using Stata version 
13.28 Subsequent analysis was undertaken using Microsoft Access and Excel. Unless 
otherwise stated, tests of statistical significance were also undertaken using Stata 13. 
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Results 
i. The population covered 
The data available from practices with adequate data quality and linkage to Hospital 
Episode Statistics included a total of 29,023 people meeting the diagnostic criteria for 
learning disability or autism. Over half (53.7%) were recorded as having a learning 
disability alone, 38.4% autism without a learning disability and 7.9% both. Between 
them they were followed for 67,799 person-years, an average of 2.34 years each. Table 
1 shows their age gender and disability profiles.  
 
Age and gender profiles for the two disability groups were very different. Figure 1 shows 
a population pyramid for the two groups. This is drawn as a histogram with bars 
representing numbers per year of age in the age band and width reflecting the number 
of years in the band. The youngest age group is arbitrarily drawn starting at 5 on the 
basis that diagnosis at younger ages is much less complete and in school data does not 
plateau until age 7. Similarly the oldest age group is arbitrarily truncated at 80 in 
recognition of reduced life expectancy. Just over half (57.4%) of those with learning 
disabilities were male, 17.2% aged under 18 and 34.2% aged 45 or older. 
Corresponding figures for the group with autism were 81.6% male, 76.5% under 18 and 
2.6% aged 45 or older.  
 
These population profiles show the patients identified as having these conditions by 
their GPs. In the case of learning disabilities the total number of adults in England 
registered by their GPs as having this condition is published annually. The average 
number in the three years covered by the study was 188,920. Our study found 14,802 
people with learning disabilities aged 18 and over. The effective coverage of the data 
source can therefore be estimated at 7.8% of the people in England known to their GP 
as having a learning disability. It may be slightly smaller if a substantial number of 
people with learning disability were identified only through diagnoses not in the QOF 
data definition. Working from this figure it is possible to estimate the identified 
prevalence of learning disabilities in children as 0.35%. This is a prevalence similar to, 
though slightly lower that identified by GPs in adulthood, but much smaller than the 
figure identified in schools or in the national child psychiatric morbidity survey 
(discussed below).29,30    
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Figure 1. Population pyramids for patients identified as having learning disability (with or without autism) 
and autism but not learning disabilities.  
 
 
 
Table 1. Age, gender and diagnosis profile of people in the study group.  
Age Group 
Learning disabilities 
Autism without learning 
disabilities 
Proportion with LD also 
recorded as having Autism 
Female Male Persons Female Male Persons Female Male Persons 
Age <18 1064 2021 3085 1513 7008 8521 12% 31% 25% 
Age 18-24 979 1644 2623 273 1236 1509 14% 27% 22% 
Age 25-44 2693 3366 6059 188 628 816 7% 14% 11% 
Age 45-64 2272 2611 4883 63 191 254 4% 8% 6% 
Age 65+ 609 628 1237 9 27 36 2% 3% 2% 
Total 7617 10270 17887 2046 9090 11136 7% 17% 13% 
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There is no corresponding published total for the number of people known by their GP 
to have autism. However, epidemiological studies of the prevalence of autism suggest 
that contrary to the numbers identified by GP's, it varies relatively little with age. The 
2004 UK survey of the mental health of children and young people in Great Britain 
found a prevalence in children of 0.8%, whilst the 2007 UK adult psychiatric morbidity 
survey reported the prevalence to be 1.1% of the population at age 16-44 falling to 0.8% 
in those aged 75 and older.31,32 These reports do not publish confidence intervals, but in 
view of the sample size the rates for younger and older adults may well not differ to a 
statistically significantly extent. The numbers of children with autism seen in our data, 
assuming they represent 7.8% of the children in England, imply a prevalence of 1.4% - 
a slightly high figure. However, the numbers of adults at all subsequent ages was far 
below what would be expected and suggests GPs only record autism in a small fraction 
of adults with the condition. It seems likely that the ones that are identified are amongst 
the most disabled.  
 
We considered reporting separately on the experience of people recorded as having 
both learning disabilities and autism. However from the numbers recorded as having 
both conditions it looked as if the recording of autism in the context of learning 
disabilities was too incomplete for this to be done reliably.  Emerson and Baines, on the 
basis of a literature review, concluded that a reasonable working estimate of the 
prevalence of autism in adults with learning disabilities would be 20% to 33%.33 Table 1 
shows that the youngest two age groups show roughly this proportion. However at older 
ages the level of recognition of autism falls sharply. Emerson and Baines also estimated 
that the prevalence of learning disabilities in children with autism could reasonably be 
taken as between 40% and 67%. This suggests that LD is under recorded in children by 
GPs even in situations where, because of the presence of identified autism it might be 
supposed that their intellectual capacity would have been carefully assessed. Our 
figures show 17% of children and young people identified as having autism were also 
identified as having a learning disability, a proportion that rose with age to 44% at age 
25 to 44 and 54% in those aged 45 to 64.  
 
Whilst we have not systematically reported the experience of people identified by their 
GPs as having both conditions as we do not consider they are identified sufficiently 
systematically  we do comment on how these differ.  
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ii Exposure to the drugs studied 
Table 2 shows the pattern of exposure to the main groups of drugs. In the commentary 
that follows, age patterns are not described in depth for people with autism as rates at 
ages above 24 were based on relatively small numbers. Annex table 1 provides a full 
breakdown of the rates of exposure to drugs of all of the sub-sections of these four BNF 
sections by gender, disability and age group.  An important general point to make about 
the observations reported in this section is that the data told us the proportion of patient 
days in each group exposed to each type of drug.  This is like having an average 
census view. However it does not tell us how many of the individuals studied were 
exposed (perhaps for short periods) to each at any time in the overall study period. 
 
 
Hypnotics 
Hypnotics were being prescribed on 3.0% of person days observed in the period for 
people with learning disabilities and the same proportion for people with autism. They 
were prescribed across the age spectrum. Rates were slightly higher for males up to the 
age of 25 and for females at older ages. Hypnotics were prescribed in learning 
disabilities more for children and people in middle age with rates lower in young 
adulthood.  In future work it would be useful to explore how much of the hypnotic 
prescribing is of melatonin. Although not a licensed indication, the BNF for children 
reports that some clinicians believe this is useful in treating initial insomnia in children 
with autism, cerebral palsy and learning disabilities. Murray and her colleagues draw 
attention to the parallel rise in prescribing of sleep medication and psycho-stimulants 
(which we did not study) for children and young people with autism who are also 
diagnosed as having attention deficit hyperactivity disorder.6 For children and young 
people diagnosed as having both learning disabilities and autism, hypnotics were being 
prescribed on 7.2% of person days, twice the rate for those identified as having only 
one of the conditions.    
 
Anxiolytics 
Overall, anxiolytics were being prescribed to 3.6% of people with learning disabilities at 
any point in time. Rates of prescribing rose with age from 0.6% of person days in people 
aged under 18 rising to 5% in middle age. For people with autism the rate in those 
under 18 was 0.1%; this rose to around 3% in adulthood. There was no substantial 
gender difference in either case. For adults identified as having both learning disabilities 
and autism, the rate was roughly double the rate for people only identified as having 
learning disabilities.  
Prescribing of psychotropic drugs to people with learning disabilities 
23 
Table 2. Rates of exposure, as percentage of person years exposed, to drugs of each BNF section by age, 
gender and disability group. 
 
BNF Group / sub group 
and Age group 
Learning disabilities Autism without learning disabilities 
Female Male Female Male 
4.1.1. Hypnotics 
 
  
  
 
Age <18 3.6 (2.9 to 4.3) 4.4 (3.9 to 5.1) 3.9 (3.4 to 4.6) 3.1 (2.8 to 3.4) 
 
Age 18-24 1.6 (1.1 to 2.2) 2.2 (1.7 to 2.7) 2.5 (1.5 to 4.3) 1.3 (0.9 to 1.9) 
 
Age 25-44 2.2 (1.8 to 2.6) 2.2 (1.9 to 2.6) 2.4 (1.3 to 4.4) 2.4 (1.7 to 3.4) 
 
Age 45-64 4.1 (3.6 to 4.7) 3.1 (2.7 to 3.6) 5.4 (2.9 to 10.0) 2.9 (1.7 to 4.8) 
 
Age 65+ 3.9 (3.0 to 5.1) 3.2 (2.4 to 4.3) 4.5 (0.8 to 21.8) 6.8 (2.7 to 16.2) 
 All ages 3.0 (2.8 to 3.3) 3.0 (2.7 to 3.2) 3.7 (3.2 to 4.3) 2.9 (2.6 to 3.1) 
4.1.2. Anxiolytics 
 
  
  
 
Age <18 0.5 (0.3 to 0.8) 0.7 (0.5 to 1.0) 0.3 (0.1 to 0.5) 0.0 (0.0 to 0.1) 
 
Age 18-24 1.7 (1.2 to 2.3) 1.9 (1.5 to 2.4) 1.0 (0.4 to 2.3) 0.7 (0.4 to 1.1) 
 
Age 25-44 3.4 (3.0 to 3.9) 4.4 (3.9 to 4.8) 3.9 (2.4 to 6.2) 2.8 (2.0 to 3.8) 
 
Age 45-64 5.5 (5.0 to 6.2) 5.4 (4.9 to 6.0) 2.4 (0.9 to 6.0) 3.3 (2.0 to 5.4) 
 
Age 65+ 6.1 (5.0 to 7.5) 4.5 (3.6 to 5.8) 0.0 (0.0 to 14.9) 3.4 (0.9 to 11.5) 
 All ages 3.6 (3.4 to 3.9) 3.5 (3.3 to 3.8) 0.7 (0.5 to 1.0) 0.4 (0.3 to 0.5) 
4.2.1. Antipsychotic 
drugs 
 
  
  
 
Age <18 1.4 (1.0 to 1.9) 2.9 (2.4 to 3.4) 1.6 (1.2 to 2.0) 1.4 (1.3 to 1.6) 
 
Age 18-24 7.0 (6.0 to 8.2) 8.7 (7.8 to 9.7) 6.4 (4.6 to 8.9) 5.1 (4.3 to 6.1) 
 
Age 25-44 11.5 (10.7 to 12.3) 16.7 (15.9 to 17.5) 13.6 (10.6 to 17.2) 10.6 (9.0 to 12.3) 
 
Age 45-64 21.0 (19.9 to 22.1) 23.2 (22.2 to 24.3) 6.6 (3.7 to 11.5) 14.5 (11.5 to 18.0) 
 
Age 65+ 27.1 (24.8 to 29.6) 26.4 (24.1 to 28.7) 0.0 (0.0 to 14.9) 11.9 (5.9 to 22.5) 
 All ages 13.6 (13.1 to 14.1) 15.0 (14.5 to 15.4) 3.3 (2.8 to 3.8) 2.7 (2.5 to 2.9) 
4.3. All Antidepressants 
 
  
  
 
Age <18 1.2 (0.8 to 1.7) 1.2 (0.9 to 1.6) 1.8 (1.4 to 2.3) 1.0 (0.9 to 1.2) 
 
Age 18-24 9.9 (8.7 to 11.2) 6.9 (6.1 to 7.8) 16.6 (13.6 to 20.0) 8.0 (7.0 to 9.2) 
 
Age 25-44 18.0 (17.1 to 19.0) 14.2 (13.4 to 15.0) 31.6 (27.3 to 36.2) 22.5 (20.4 to 24.8) 
 
Age 45-64 25.0 (23.9 to 26.2) 18.2 (17.2 to 19.2) 32.5 (25.9 to 40.0) 28.7 (24.8 to 33.0) 
 
Age 65+ 24.0 (21.8 to 26.4) 18.6 (16.7 to 20.7) 31.8 (16.4 to 52.7) 22.0 (13.4 to 34.1) 
 All ages 17.2 (16.7 to 17.8) 11.8 (11.4 to 12.2) 7.0 (6.3 to 7.7) 3.8 (3.5 to 4.0) 
4.8 All Antiepileptic 
drugs 
 
  
  
 
Age <18 11.5 (10.3 to 12.8) 9.5 (8.7 to 10.4) 3.4 (2.9 to 4.0) 1.7 (1.5 to 1.9) 
 
Age 18-24 20.4 (18.7 to 22.2) 16.1 (14.9 to 17.4) 8.8 (6.6 to 11.5) 4.3 (3.6 to 5.2) 
 
Age 25-44 21.6 (20.6 to 22.7) 23.3 (22.4 to 24.3) 12.6 (9.8 to 16.2) 6.2 (5.0 to 7.6) 
 
Age 45-64 25.8 (24.6 to 27.0) 25.9 (24.8 to 27.0) 12.0 (7.9 to 17.9) 11.2 (8.6 to 14.4) 
 
Age 65+ 24.5 (22.3 to 26.8) 21.2 (19.1 to 23.4) 0.0 (0.0 to 14.9) 23.7 (14.7 to 36.0) 
 
All ages 21.5 (20.9 to 22.1) 20.0 (19.5 to 20.5) 5.0 (4.4 to 5.7) 2.6 (2.3 to 2.8) 
Figures in parentheses are 95% confidence intervals. See methods section for details 
 
Antipsychotics  
Overall, 16.6% of people with learning disabilities were being prescribed some drug 
from the class ‘drugs used in psychoses and related disorders’ (BNF 4.2). The most 
widely used sub-group of these (antipsychotic drugs - sub-section 4.2.1) were being 
given to 14.4% of people with learning disabilities. There were major age and gender 
differences. Among those aged under 18, 2.4% of those with learning disabilities and 
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1.5% with autism alone were being prescribed antipsychotics; corresponding figures for 
adults were 17.0% and 8.2%. In those with learning disabilities the proportion rose fairly 
steadily with age: 8.1% at age 18 to 24, 14.3% at 25-44, 22.2% at 45 to 64, and 26.7% 
at ages over 65. The gradation was less marked in adults with autism and we cannot be 
so confident about it as the observations were based on much smaller numbers of 
patients. Very few patients with either learning disabilities or autism were receiving 
depot antipsychotic agents (BNF section 4.2.2). Across the age spectrum the proportion 
of people identified as having both learning disabilities and autism being prescribed 
antipsychotics was substantially higher than in those identified as having learning 
disabilities alone. The difference was sixfold in those aged under 18, falling to roughly 
threefold in most of the adult years; in those aged over 65 the difference fell to two and 
a half times.  
 
Drugs for the treatment of mania and hypomania (BNF sub-section 4.2.3) were being 
prescribed for 5.9% of patients with learning disabilities. Prescribing was rare for 
patients under age 18 but rose steadily through the adult age groups steadying after the 
age of 65. There was no obvious gender difference. Anti-manic drugs were being 
prescribed for fewer people identified as having autism alone. As with learning 
disabilities, this was very rare under the age of 18 (0.2%), rising again in the adult age 
groups to a peak of 7.6% in the 45 to 64 year old band.  
 
Antidepressants 
Antidepressants were being prescribed overall to 14.1% of people with learning 
disabilities. From little more than 1% in both groups at ages under 18, prescribing rates 
rose sharply through adult age bands to peaks in the 45 to 64 age band of 21.4% for 
adults with learning disabilities and 29.7% for those with autism but not learning 
disabilities. Women with learning disabilities were about 45% more likely to be receiving 
antidepressants at any time than men, There was a similar gender difference for people 
with autism. Children and young people identified as having both autism and learning 
disabilities were six times as likely to be being prescribed antidepressants as those 
identified as having only learning disabilities and three times as likely as those only 
identified as having autism.     
 
The most commonly used sub-class of antidepressants was selective serotonin re-
uptake inhibitors (SSRIs). These accounted for 70% of the person years exposure to 
antidepressants for people with learning disabilities and 75% for people with autism but 
not learning disabilities. Tricyclics (BNF 4.3.1) and ‘other’ antidepressants (BNF 4.3.4)3 
accounted for the rest in almost equal shares.  The higher rates of prescribing in 
                                            
 
3
 BNF sub-section 4.3.4 includes agomelatine, duloxetine, flupentixol, mirtazapine, nefazodone, reboxetine, 
tryptophan and venlafaxine. 
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children and adolescents with both learning disabilities and autism noted above were 
almost entirely attributable to use of SSRIs.   
 
Antiepileptics  
Overall, 20.6% of people with learning disabilities were being prescribed anti-epileptic 
drugs (BNF 4.8). In people with learning disabilities, the rate in those aged under 18 
was 10.2% but this rose to 17.7% at ages 18 to 24 and more than 20% in older ages. 
There was no consistent gender difference.  In people with autism but not learning 
disabilities, 2.0% of those aged under 18 were being prescribed drugs in this class. This 
rose to 5.1% at age 18 to 24 and higher rates at older ages. In younger people with 
autism, drugs for control of epilepsies were being prescribed twice as commonly for 
females as for males at any time. Drugs used to control status epilepticus were being 
prescribed for 4.4% of people with learning disabilities and 0.5% of those with autism 
alone. 
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iii. Variation 
We undertook a number of stratified analyses of the exposure data. There were 
substantial differences between geographic regions in rates of exposure to all four 
groups of drugs. In all but anti-epileptics, the highest regional exposure rate was double 
the lowest. For anti-epileptics the highest regional rate was 1.7 times the lowest. We 
explored whether regional prescribing rates for drugs from the various BNF sections we 
studied were correlated. For the most part they were not. However regional rates of 
prescribing of anti-epileptic drugs were significantly correlated with rates of prescribing 
of anxiolytics and antipsychotics (antiepileptics with anxiolytics, Spearman’s 
rho=0.8788, p=0.0008, antiepileptics with antipsychotics, rho=0.867, p=0.0012).  Rates 
of prescribing anxiolytics and antipsychotics were also significantly, though less 
strongly, correlated with each other (rho=0.661, p=0.0376).  
There was little evidence of changes over the three years studied, the only exception to 
this being that for selective serotonin re-uptake inhibitors the rate of exposure in the first 
year was significantly lower than the overall rate, and the rate in the third significantly 
higher.  
 
It is difficult to interpret these patterns as we do not know how uniform they were across 
the age, gender and disability sub-groups for which we have reported other findings.   
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iv. Patterns of prescribing 
Duration of prescribing 
Figure 2 illustrates two aspects of the pattern of prescribing; the detailed numbers for 
these charts are shown in Annex table 2 (page 60). The upper two charts show the 
proportion of time for which patients were exposed to the drugs in which the prescribing 
episode was not confined to a single prescription - in other words where the prescription 
involved was followed by another prescription for the same patient for a drug from the 
same BNF section / sub-section. The charts show that for both people with learning 
disabilities and people with autism but not learning disabilities, most prescribing of all of 
the drugs studied was longer term. The slight exceptions to this were anxiolytics, where 
for adults with learning disabilities 11.1% of prescriptions and for children and young 
people 19.6% involved single prescriptions and 13.5% for people with autism but not 
learning disabilities involved single prescriptions. This also applied to 9.6% of 
prescriptions for hypnotics to people with autism. In all other cases 95% or more of 
exposure was in treatment episodes involving two or more prescriptions. In all cases, 
single prescription treatment episodes were more common in those aged under 18 than 
in older people. 
 
 
Use of multiple drugs 
The lower two charts in  Figure 2 show the proportion of prescribing exposure where 
more than one drug in the BNF section / sub-section was prescribed simultaneously. 
This was relatively unusual. However, for patients with learning disabilities, within-
section/sub-section multiple drug prescribing was seen for antipsychotics in 22.5% of 
prescriptions for adults and 7% for children and young people, and for antidepressants 
10.8% (adults) and 5.7% (children and young people). In the case of antipsychotics this 
may be a slight underestimate because depot injectable preparations of antipsychotics 
are grouped in a separate sub-section from other preparations. Thus a patient recorded 
as having been prescribed a single depot injectable antipsychotic and a single oral 
antipsychotic would not have been classified as receiving multiple prescribing for either 
sub-group. As prescribing of depot injectable antipsychotics was rare, this is not likely to 
have had a major effect. For patients with autism but not learning disabilities, 
corresponding figures were: antipsychotics 16.1% and 8.3%, antidepressants:1.03% 
and 3.7%. Multi-drug use was seen for higher proportions of treatment episodes with 
anti-epileptics (for people with learning disabilities 43.3% for adults and 27.9% cor 
children and young people, for people with autism 31.4% and 27.3%). This is less 
surprising since multiple-drug strategies have recognised purposes in the treatment of 
epilepsies.34 In most cases multi-drug prescribing was less common in those aged 
under 18 than in older people. An exception was for hypnotics. 
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In addition to use of multiple drug compounds within BNF sections/sub-sections, we 
looked at the extent to which people being treated with drugs in each section were also 
receiving drugs from other sections. We did this by using a single randomly chosen 
sample day for each included patient. The results are in Table 3. A small number of 
patients were excluded from this analysis because they were in hospital on the selected 
day (2.0% of patients with learning disabilities (358/17,887) and 0.5% (54/11,136) with 
autism but not learning disabilities).  
 
On the randomly selected day, 63.4% of people with learning disabilities and 88.9% with 
autism were not being prescribed drugs in any of the sections studied. These figures 
are not directly comparable because they varied substantially with age and the patients 
with autism were a much younger group. Table 4 shows that under age 18, 85.3% of 
people with learning disability and 93.1% with autism were not being prescribed any of 
the drugs studied. The proportions not prescribed drugs fell and the average number of 
drugs prescribed rose with age. 
 
The pattern of prescribing of drugs of multiple BNF sections differed between patients 
with learning disabilities and those with autism but not learning disabilities. Considering 
adults with learning disabilities, of those prescribed antipsychotics, overall 67.2% were 
prescribed drugs in at least one other class, most commonly anti-depressants (40.0%) 
and anticonvulsants (38.0%). Of those prescribed antidepressants, 59.3% were also 
prescribed at least one other class of drug, most commonly antipsychotics (40.4%). Of 
those prescribed anxiolytics, 96.2% were prescribed at least one other drug class with 
49.2% prescribed an antipsychotic, 40.6% an antidepressant and 75.5% an 
anticonvulsant. Of those prescribed hypnotics, 85.6% were prescribed another drug 
class, 48.4% an antipsychotic, 42.4% an antidepressant and 41.9% an anticonvulsant. 
Anticonvulsants were the group most commonly prescribed without drugs from other 
sections (52.2%). Of those prescribed an anticonvulsant, 28.8% were also prescribed 
an antipsychotic, 22.4% an antidepressant, 14.8% an anxiolytic and 5.2% a hypnotic. 
Corresponding figures for children and young people with learning disabilities and for 
people with autism can be seen in Table 3. 
 
Compared to those under to those aged over 18, children and young people with autism 
alone prescribed hypnotics, antipsychotics or antidepressants were less likely than 
those with learning disabilities to be prescribed drugs of another class as well.  
As people got older, the chance that they were not prescribed any of the five classes of 
drugs considered in this section fell. This was the case for both those with learning 
disabilities (chi square for trend = 1152.7, df=1, p<0.0001) and autism (chi square for 
trend = 865.3, df=1, p<0.0001).  For those prescribed at least one type, the average 
number of types used rose with age. This was also true for both those with learning 
disabilities (adjusted R-squared = 0.017, F(1,6422)=113.3, P<0.0001) and autism 
(adjusted R-squared = 0.055, F(1,1230)=72.0, P<0.0001).   
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Figure 2. Patterns of prescribing. Upper two charts show proportion of exposure in ‘ongoing’ treatment episodes, lower two show proportion in 
episodes involving more than one drug compound in the BNF section / sub-section 
Proportion (percentage) of treatment in ‘on-going’ episodes  
  
Proportion (percentage) of treatment involving more than one compound in class 
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Table 3. Cross-sectional analysis of combinations of drugs from different BNF sections.  
  
  Learning disabilities 
Autism without learning 
disabilities 
      
Aged under 
18 
Aged 18 and 
older 
Aged under 
18 
Aged 18 and 
older 
Anxiolytics (BNF 
4.1.1)   
 
  
  
 
Number (%) exposed on random day 17 (0.6%) 640 (4.4%) 9 (0.1%) 54 (2.1%)
Taking just Anxiolytics 5.9% 3.8% 11.1% 3.7% 
 
Also taking: Hypnotics 23.5% 10.3% 22.2% 24.1% 
  
Antipsychotics 5.9% 49.2% 22.2% 31.5% 
  
Antidepressants 11.8% 40.6% 11.1% 55.6% 
  
Anticonvulsants 94.1% 75.5% 88.9% 88.9% 
 Average number of the 5 drug classes  2.4 2.8 2.4 3.0 
Hypnotics (BNF 
4.1.2)   
 
  
  
 
Number (%) exposed on random day 118 (3.9%) 403 (2.8%) 265 (3.1%) 50 (1.9%)
 
Taking just Hypnotics 62.7% 14.4% 80.8% 30.0% 
 
Also taking: Anxiolytics 3.4% 16.4% 0.8% 26.0% 
  
Antipsychotics 9.3% 48.4% 10.6% 26.0% 
  
Antidepressants 3.4% 42.4% 4.5% 44.0% 
  
Anticonvulsants 28.8% 41.9% 8.3% 36.0% 
 Average number of the 5 drug classes  1.4 2.5 1.2 2.3 
Antipsychotics (BNF 4.2.1 and 4.2.2) 
 
  
  
 
Number (%) exposed on random day 70 (2.3%) 2,476 (17.1%) 135 (1.6%) 208 (8.1%)
Taking just Antipsychotics 50.0% 32.8% 65.9% 38.5% 
 
Also taking: Anxiolytics 1.4% 12.7% 1.5% 8.2% 
  
Hypnotics 15.7% 7.9% 20.7% 6.3% 
  
Antidepressants 18.6% 40.0% 13.3% 47.1% 
  
Anticonvulsants 25.7% 38.0% 6.7% 24.5% 
 Average number of the 5 drug classes  1.6 2.0 1.4 1.9 
Antidepressants 
(BNF 4.3)   
 
  
  
 
Number (%) exposed on random day 34 (1.1%) 2,450 (16.9%) 96 (1.1%) 418 (16.2%)
Taking just Antidepressants 52.9% 40.7% 69.8% 64.4% 
 
Also taking: Anxiolytics 5.9% 10.6% 1.0% 7.2% 
  
Hypnotics 11.8% 7.0% 12.5% 5.3% 
  
Antipsychotics 38.2% 40.4% 18.8% 23.4% 
  
Anticonvulsants 14.7% 29.9% 9.4% 15.3% 
 Average number of the 5 drug classes  1.7 1.9 1.4 1.5 
Anticonvulsants 
(BNF 4.8)   
 
  
  
 
Number (%) exposed on random day 302 (9.9%) 3,266 (22.6%) 178 (2.1%) 187 (7.3%)
Taking just Anticonvulsants 79.8% 52.2% 77.5% 43.9% 
 
Also taking: Anxiolytics 5.3% 14.8% 4.5% 25.7% 
  
Hypnotics 11.3% 5.2% 12.4% 9.6% 
  
Antipsychotics 6.0% 28.8% 5.1% 27.3% 
  
Antidepressants 1.7% 22.4% 5.1% 34.2% 
 Average number of the 5 drug classes  1.2 1.7 1.3 2.0 
n (People in group not in hospital on the 
random selected day)       3,052      14,477        8,504        2,578  
 
The table shows data relating to a single randomly chosen sample day for each individual in the study. A 
number of individuals were excluded from this analysis because they were in hospital on the selected day.  
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Table 4 Proportion of people prescribed none of the drugs and average of groups 
prescribed by those prescribed at least one by age and diagnostic group 
Diagnostic and age 
group 
% prescribed 
none of the 
drugs studied 
Average drug groups 
among those 
prescribed at least 
one 
n 
Learning disabilities 
   
 
Age <18 85.3% 1.2 3052 
 
Age 18-24 72.8% 1.3 2573 
 
Age 25-44 61.1% 1.5 5951 
 
Age 45-64 50.9% 1.6 4767 
  Age 65+ 48.0% 1.5 1186 
Autism 
   
 
Age <18 93.1% 1.2 8504 
 
Age 18-24 82.2% 1.3 1491 
 
Age 25-44 68.5% 1.5 807 
 
Age 45-64 56.3% 1.5 247 
 
Age 65+ 51.5% 1.6 33 
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Drugs given in high doses 
There was limited data available for this aspect of the study due to the nature of GP 
recording of dosage information. Doses were not clearly identifiable in 28.6% of 
prescriptions for hypnotics, 55.3% for anxiolytics, 25.9% for antipsychotics, 16.7% for 
antidepressants and 31.2% for anti-epileptics. This was due to a large number of 
prescriptions having non-informative dosage information recorded, such as “as directed” 
or “as required”.  Annex table 5 shows the frequency of this uncertainty for all drug and 
patient groups. 
 
To the extent that it was informatively recorded, prescribing of most drugs in most 
groups was within BNF recommended dosage limits. Table 5 shows the extent to which 
this was not the case for the most important BNF sections / sub-sections. A fuller 
version of this table giving details for BNF sub-sections is at Annex table 6. Our 
identification of high doses here relates only to individual agents.  We did not estimate 
the cumulative effect of use of more than one drug from the same BNF section / sub-
section.  
 
The drug groups for which high-dose prescribing was most common were hypnotics and 
anxiolytics for adults with learning disabilities (2.4% of prescriptions were for high 
doses) and antipsychotics for adults with either learning disabilities (5.5%) or autism 
(5.6%). High dose prescribing was significantly more common in the youngest adult age 
group both for people with learning disabilities and for those with autism but not learning 
disabilities (18-24: learning disabilities - 10.4%, autism  8.4%). Whilst overall high dose 
prescribing of antidepressants was rare, high doses of tricyclic antidepressants were 
seen in people with autism aged both under 18 (8.7% of prescriptions) and in adulthood 
(4.6%), particularly at ages 18-24 (20.6%). 
 
Table 5. Proportion (percentage) of prescriptions for drugs where dose specified exceeded BNF 
recommended maximum 
BNF Sub group 
People with learning disabilities 
People with autism but not 
learning disabilities 
Under 18 18 and older Under 18 18 and older 
4.1.1. Hypnotics 0.2 (0.1 to 0.4) 2.4 (2.2 to 2.7) 0.4 (0.3 to 0.5) 1.7 (1.2 to 2.4) 
4.1.2. Anxiolytics 0.7 (0.3 to 1.7) 2.4 (2.2 to 2.6) 1.0 (0.3 to 2.8) 1.0 (0.6 to 1.7) 
4.2.1. Antipsychotic drugs 1.5 (1.0 to 2.1) 5.5 (5.4 to 5.7) 1.3 (1.0 to 1.7) 5.6 (5.1 to 6.2) 
4.3. All Antidepressants 0.0 (0.0 to 0.3) 0.6 (0.5 to 0.6) 0.7 (0.4 to 1.0) 1.1 (0.9 to 1.3) 
4.8 All Antiepileptic drugs 0.8 (0.6 to 0.9) 0.8 (0.8 to 0.9) 0.4 (0.3 to 0.5) 0.2 (0.1 to 0.3) 
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Drugs and indications 
As described in the methods section, we explored the association between prescribing 
of drugs and recording of recognised indications for their use by deriving lists of 
indications and searching patients’ notes for records of these conditions in relation to 
the drugs they were prescribed. This proved to be a complex task and the answers we 
were able to derive should not be considered precise.  
 
Some indications could be described by symptom terms with much wider applicability 
than that was relevant to the drug of interest. The most obvious example is the 
recognised, though rare, use of many phenothiazines, categorised as antipsychotic 
drugs (BNF sub-section 4.2.1), for the control of persistent nausea or vomiting in 
terminal care. Our code list included a range of terms for nausea as indications for this 
group of drugs. It seems likely that only a small proportion of cases where a person 
receiving a drug of this type and also recorded as suffering with nausea or vomiting 
would have fallen into the category where the drug was an appropriate treatment for this 
symptom. The tendency arising from this would have been for us to err in the direction 
of rating prescriptions as indicated when the record on which this was based may not 
have provided an adequate basis. The following results should be considered in this 
light. 
 
It is also important to remember that we do not know whether appropriate clinical 
indications for the drugs were present, only whether they were recorded as being 
present. So absence of indications could be a sign or either poor practice or poor 
notekeeping. 
 
We show the findings from this part of the study in three tables. The first (Table 6) 
shows the proportion of prescriptions from each BNF section or sub-section for which a 
recognised indication was recorded. The second (Figure 3) shows the timing of 
recorded indications in relation to prescriptions. The third ( 
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Table 7) shows the proportion of prescriptions from each BNF section for which each of 
the various possible iindications was recorded.  
 
Table 6 shows the proportions of prescriptions where the case notes also included a 
report of a recognised indication. These varied considerably between drug groups. High 
proportions of prescriptions for drugs used in the control of the epilepsies had records of 
relevant indications. The overall prevalence of exposure to antiepileptics in people with 
learning disabilities was similar to estimates of epilepsy prevalence for this group so for 
this  is not surprising. For adults with autism but not learning disabilities, the prescribing 
rate climbs strikingly and surprisingly with age (Table 2).  The high proportion of 
prescriptions for which there is an appropriate indication (80.6%) seems surprising.  
 
Prescriptions for drugs in the BNF section for drugs used in psychoses and related 
disorders had an appropriate accompanying diagnosis in 16.4% of cases for children 
and young people and 49.6% for adults. Within this overall section prescriptions for 
drugs in the sub-section for drugs used for mania and hypomania were most commonly 
accompanied by a record of a recognised indication (94.8% prescriptions for children 
and young people and 68.0% for adults with learning disabilities, and 68.4% and 73.5% 
of prescriptions for people with autism in the corresponding age groups). Prescriptions 
for compounds in the sub-section covering anti-psychotic drugs were less likely to be 
associated with records of recognised indications.  
 
For antidepressants, 46% of prescriptions for children and young people in both 
diagnostic groups had a relevant indication recorded as did 68.2% of adults with 
learning disabilities and 83.2 prescriptions for adults with autism but not learning 
disabilities.  
 
Hypnotics had relevant indications reported in 22.2% of prescriptions for children and 
young people with learning disabilities and 24.2% for those with autism. For adults, 
hypnotic prescribing was associated with relevant indications in 44.1% of cases for 
individuals with learning disabilities and 34.4 of those with autism.  Anxiolytic prescribing 
was associated with relevant indications in 18.3% of cases for children and young 
people with learning disabilities and 21.7% with autism, 53.6% of those for adults with 
learning disabilities and 81.8% for adults with autism.  
 
Figure 3 shows the timing of records of indications for prescribing where these were 
found.  In the great majority of cases records of the indication were contemporary with 
prescriptions (recorded within 28 days). In adults with learning disabilities, in about 10% 
of cases the record of the indication preceded the prescription.  In children and in adults 
with autism this was more common. There were some exceptions where indications 
were commonly only recorded after the prescription. These included prescribing of 
anxiolytics and drugs for febrile convulsions in children with learning disabilities and 
antipsychotics in children with autism. After-prescription recording of indications was 
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also relatively common in prescribing of antipsychotics, hypnotics and antidepressants 
to children and young people with autism. Table 7 shows the frequency with which each 
type of indication identified as being potentially relevant to each category of drugs was 
recorded. The table only includes drug indications for which examples appeared in the 
data. In many cases patients were noted as having more than one possible indication. 
However, this table suggests that the extent to which usage of drugs was associated 
with recording of the normal primary indications may be a little overstated by Table 6. 
The table shows the full list of indications that we considered were recognised for each 
group of drugs. Some members of groups of drugs had additional indications. Table 7 
shows the drugs concerned. Alongside each type of indication, the second column 
records either ‘Core’ if the indication represented a primary purpose for the group, or, 
where it was an additional indication for some members of the group, the names of the 
drugs concerned. This analysis was undertaken as a late addition to the project to 
clarify the emerging findings. We did not have the resources to undertake it for all drug 
groups; it is confined to the groups of drugs in BNF sub-sections for hypnotics (4.1.1), 
anxiolytics (4.1.2), antipsychotics (4.2.1) and the sections for antidepressant and anti-
epileptic drugs.  
 
Anxiolytics are recorded as indicated in 53.6% of prescriptions for adults with learning 
disabilities (Table 6), however only 29.7% had records of anxiety states. In this case 
several others were recorded as having other types of anxiety disorder (5.4% phobias 
and 6.2% panic symptoms or disorder, although we do not know how much these 
overlap), so it is possible that the proportion with some type of anxiety disorder reached 
40% of those prescribed the drugs.  However an alternative possibility is that in many 
cases our approach was reading a diagnosis of epilepsy as a relevant indication. The 
position is similar for antipsychotic drugs – this part of the table relates to just drugs in 
BNF section 4.2.1 and 4.2.2. Table 6 shows 41.9% of prescriptions for adults with 
learning disabilities as being associated with a recognised indication. However the 
proportion having a diagnosis falling into our categories of either psychosis or bipolar 
disorder could only just have exceeded 30%, and assuming some overlap of the 
categories was probably less. In this case the vestibular symptoms (the most commonly 
recorded indication for these drugs in all four age / diagnosis groups) relate to persistent 
nausea and vomiting or travel sickness.  
 
Table 7 is more reassuring in relation to antidepressants and anti-epileptic drugs. In 
these cases the most commonly recorded type of indication is the corresponding 
primary one – depression or epilepsy. For adults with autism the rate of prescriptions of 
anti-epileptics rises with age and as noted above, the proportion reported as having 
relevant indications is high. Table 7 shows that in more than half of the cases this was 
due to records of anxiety, insomnia and bipolar disorders. 
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Table 6. Proportions (percent) of prescriptions with recognised indications recorded in casenotes. 
  
% of Prescriptions for  people with learning 
disabilities 
% of Prescriptions for people with autism but 
not learning disabilities 
BNF Sub group Under 18 18 and older Under 18 18 and older 
4.1. All Hypnotics and anxiolytics 21.6 (20.4 to 22.9) 49.6 (49.1 to 50.1) 24.2 (23.2 to 25.1) 56.4 (54.7 to 58.1) 
4.1.1. Hypnotics 22.2 (20.9 to 23.5) 44.1 (43.3 to 44.8) 24.3 (23.3 to 25.3) 34.4 (32.2 to 36.6) 
4.1.2. Anxiolytics 18.3 (15.4 to 21.5) 53.6 (53.0 to 54.2) 21.7 (17.5 to 26.5) 81.8 (79.9 to 83.7) 
4.2. All Drugs used in psychoses and related disorders 16.4 (15.0 to 18.0) 49.6 (49.3 to 49.8) 19.2 (18.1 to 20.4) 54.1 (53.0 to 55.1) 
4.2.1. Antipsychotic drugs 6.8 (5.8 to 7.9) 41.9 (41.6 to 42.1) 11.4 (10.5 to 12.5) 47.2 (46.0 to 48.4) 
4.2.2. Antipsychotic depot injections - 88.8 (86.9 to 90.4) - 100.0 (80.6 to 100.0) 
4.2.3. Drugs used for mania and hypomania 94.8 (91.5 to 96.9) 68.0 (67.6 to 68.4) 68.4 (64.9 to 71.8) 73.5 (72.0 to 75.0) 
4.3. All Antidepressants 46.0 (43.2 to 48.9) 68.2 (68.0 to 68.5) 46.1 (44.3 to 47.9) 83.2 (82.5 to 83.8) 
4.3.1. Tricyclic and related antidepressant drugs 38.2 (28.1 to 49.4) 54.1 (53.4 to 54.8) 21.8 (17.0 to 27.6) 72.4 (70.3 to 74.5) 
4.3.3. Selective serotonin re-uptake inhibitors 43.6 (40.6 to 46.7) 69.7 (69.4 to 70.1) 48.6 (46.7 to 50.6) 86.0 (85.2 to 86.7) 
4.3.4. Other antidepressant drugs 100.0 (78.5 to 100.0) 75.2 (74.5 to 75.9) 64.0 (54.2 to 72.7) 82.3 (80.7 to 83.9) 
4.8 All Antiepileptic drugs 94.2 (93.8 to 94.6) 90.7 (90.6 to 90.8) 92.0 (91.4 to 92.6) 80.6 (79.7 to 81.4) 
4.8.1 Control of the epilepsies 96.6 (96.2 to 96.9) 93.5 (93.4 to 93.6) 93.8 (93.2 to 94.3) 80.1 (79.1 to 81.0) 
4.8.2 Drugs used in status epilepticus 70.4 (67.8 to 72.8) 74.6 (74.1 to 75.1) 67.7 (63.6 to 71.5) 84.4 (82.4 to 86.3) 
4.8.3 Febrile convulsions 41.7 (32.8 to 51.1) 55.0 (54.2 to 55.9) 41.3 (32.5 to 50.7) 85.1 (82.9 to 87.1) 
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Figure 3. Timing of indications in relation to prescriptions. Charts show the proportion of prescriptions for which some recognised indication was 
identified where this was recorded within 28 days of the prescription or before or after this. Numbers after drug section labels are counts of 
prescriptions     
People with learning disabilities People with autism but not learning disabilities 
  
Under 18 Under 18 
  
Aged 18 and older Aged 18 and older 
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Table 7. Specific indications recorded in notes in association with drugs from BNF sections / sub-sections. The table shows number exposed to 
relevant drugs followed by the proportion (with 95% C.I.) in whose notes each potential clinical reason is recorded. 
   
Type of indication 
Specific drugs in the groups 
concerned where not general 
Learning disabilities Autism without learning disabilities 
  Under 18 18 and older Under 18 18 and older 
Hypnotics (4.1.1)       
 Patients exposed   275 1168 737 227 
 Nausea and vomiting Promethazine 34.9 (29.5 to 40.7) 32.7 (30.1 to 35.4) 30.4 (27.2 to 33.8) 20.7 (15.9 to 26.4) 
 Insomnia (Core) 20.4 (16.0 to 25.5) 42.6 (39.8 to 45.5) 21.8 (19.0 to 25.0) 44.5 (38.2 to 51.0) 
 Anxiety Chlormethiazole (restlessness 
and agitation in the elderly) 
7.3 (4.8 to 11.0) 35.1 (32.4 to 37.9) 8.7 (6.9 to 10.9) 55.9 (49.4 to 62.3) 
  Alcohol withdrawal Chlormethiazole   0.4 (0.2 to 1.0)   1.3 (0.5 to 3.8) 
Anxiolytics (4.1.2)       
 Patients exposed   109 2259 76 219 
 Epilepsy Diazepam, Lorazepam 61.5 (52.1 to 70.1) 46.2 (44.2 to 48.3) 30.3 (21.1 to 41.3) 17.4 (12.9 to 22.9) 
 Insomnia Diazepam, Lorazepam, 
Oxazepam 
7.3 (3.8 to 13.8) 17.4 (15.9 to 19.1) 10.5 (5.4 to 19.4) 30.1 (24.4 to 36.5) 
 Anxiety (Core) 6.4 (3.1 to 12.7) 29.7 (27.8 to 31.6) 28.9 (20.0 to 40.0) 62.6 (56.0 to 68.7) 
 Phobias (Core) 5.5 (2.5 to 11.5) 5.4 (4.5 to 6.4) 7.9 (3.7 to 16.2) 16.4 (12.1 to 21.9) 
 Panic  (Core) 3.7 (1.4 to 9.1) 6.2 (5.3 to 7.3) 6.6 (2.8 to 14.5) 22.8 (17.8 to 28.8) 
 Alcohol withdrawal Diazepam, Chlordiazepoxide  0.2 (0.1 to 0.5)  1.4 (0.5 to 3.9) 
 Dystonia Diazepam  0.1 (0.0 to 0.4)   
 For sedation Lorazepam  0.8 (0.5 to 1.2)  0.5 (0.1 to 2.5) 
  Social anxiety (Core)   0.2 (0.1 to 0.5)   4.1 (2.2 to 7.6) 
Antipsychotic drugs (4.2.1)       
 Patients exposed   182 3470 325 378 
 Nausea, vomiting and allergic 
indications specific to  
Perphenazine
4
,  42.3 (35.4 to 49.6) 34.9 (33.3 to 36.5) 36.9 (31.9 to 42.3) 30.4 (26.0 to 35.2) 
 Persistent nausea and 
vomiting 
Prochlorperazine, 34.1 (27.6 to 41.2) 28.4 (26.9 to 29.9) 29.2 (24.6 to 34.4) 21.7 (17.8 to 26.1) 
 Anxiety Chlorpromazine, Pericyazine, 
Perphenazine, Trifluoperazine, 
12.6 (8.6 to 18.2) 26.1 (24.6 to 27.5) 13.2 (10.0 to 17.3) 47.1 (42.1 to 52.1) 
 Depression Flupentixol, Quetiapine 9.9 (6.3 to 15.1) 35.8 (34.2 to 37.4) 12.3 (9.2 to 16.3) 54.5 (49.5 to 59.4) 
 Psychosis (Core) 3.3 (1.5 to 7.0) 22.5 (21.2 to 24.0) 3.1 (1.7 to 5.6) 25.7 (21.5 to 30.3) 
 Bipolar disorder (Core) 2.2 (0.9 to 5.5) 9.2 (8.2 to 10.2) 2.8 (1.5 to 5.2) 10.3 (7.6 to 13.8) 
Antipsychotic drugs cont.      
 Antisocial sexual behaviour Benperidol  0.3 (0.2 to 0.6)   
                                            
 
4
 The list of allergic indications for perphenazine was so wide and so potentially common that we used a separate list of physical indications for this drug. 
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Type of indication 
Specific drugs in the groups 
concerned where not general 
Learning disabilities Autism without learning disabilities 
  Under 18 18 and older Under 18 18 and older 
 Monosymptomatic 
hypochondriacal psychosis 
(Core, but specifically 
Pimozide) 
 0.2 (0.1 to 0.5) 0.3 (0.1 to 1.7) 0.8 (0.3 to 2.3) 
  Hiccup Chlorpromazine, Haloperidol   0.3 (0.2 to 0.5)     
Antidepressants (4.3)       
 Patients exposed   102 3712 292 755 
 Depression (Core) 33.3 (24.9 to 42.9) 61.5 (59.9 to 63.0) 37.0 (31.7 to 42.7) 76.3 (73.1 to 79.2) 
 Anxiety Trazodone, Paroxetine, 
Escitalopram, Duloxetine, 
Venlafaxine 
24.5 (17.2 to 33.7) 39.3 (37.7 to 40.9) 33.9 (28.7 to 39.5) 54.8 (51.3 to 58.4) 
 Epilepsy Pregablin 16.7 (10.7 to 25.1) 26.1 (24.7 to 27.5) 10.3 (7.3 to 14.3) 8.9 (7.0 to 11.1) 
 Enuresis Imipramine 9.8 (5.4 to 17.1) 4.9 (4.2 to 5.6) 9.6 (6.7 to 13.5) 5.6 (4.1 to 7.4) 
 Obsessive compulsive 
disorder 
Clomipramine, Escitalopram, 
Fluoxetine, Fluvoxamine, 
Paroxetine, Sertraline 
8.8 (4.7 to 15.9) 4.7 (4.1 to 5.4) 10.3 (7.3 to 14.3) 12.6 (10.4 to 15.1) 
 Panic Citalopram, Escitalopram, 
Paroxetine, Sertraline 
7.8 (4.0 to 14.7) 9.3 (8.5 to 10.3) 4.8 (2.9 to 7.9) 12.2 (10.0 to 14.7) 
 Phobia Clomipramine 5.9 (2.7 to 12.2) 5.9 (5.2 to 6.7) 3.4 (1.9 to 6.2) 11.7 (9.6 to 14.1) 
 Psychosis (Core) 2.9 (1.0 to 8.3) 11.5 (10.5 to 12.6) 1.7 (0.7 to 3.9) 9.5 (7.6 to 11.8) 
 Bipolar disorder (Core) 2.0 (0.5 to 6.9) 4.0 (3.5 to 4.7) 1.7 (0.7 to 3.9) 4.8 (3.5 to 6.5) 
 Bulimia Fluoxetine 1.0 (0.2 to 5.3) 0.3 (0.1 to 0.5) 0.7 (0.2 to 2.5) 0.8 (0.4 to 1.7) 
 Cataplexy Clomipramine     0.5 (0.2 to 1.4) 
  Social anxiety Escitalopram, Paroxetine, 
Sertraline 
  0.2 (0.1 to 0.4)   2.1 (1.3 to 3.4) 
 Chronic pain Amitryptaline, Nortryptaline  1.7 (1.3 to 2.2)  1.6 (0.9 to 2.8) 
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Type of indication 
Specific drugs in the groups 
concerned where not general 
Learning disabilities Autism without learning disabilities 
  Under 18 18 and older Under 18 18 and older 
Anti-epileptic drugs (4.8)       
 Patients exposed   429 4295 301 353 
 Epilepsy (Core) 85.3 (81.7 to 88.4) 70.9 (69.5 to 72.3) 74.8 (69.6 to 79.3) 39.4 (34.4 to 44.6) 
 Insomnia Clormethiazole 8.4 (6.1 to 11.4) 13.0 (12.0 to 14.0) 9.6 (6.8 to 13.5) 22.7 (18.6 to 27.3) 
 Anxiety Pregablin, Clobazam 4.2 (2.7 to 6.5) 20.2 (19.0 to 21.4) 11.6 (8.5 to 15.7) 46.7 (41.6 to 52.0) 
 Chronic pain including 
Trigeminal Neuralgia 
Carbamazepine, Gabapentin, 
Pregablin, Phenytoin 
0.7 (0.2 to 2.0) 0.9 (0.7 to 1.2)  2.3 (1.2 to 4.4) 
 
 Bipolar disorder Carbamazepine, Sodium 
Valproate, 
0.5 (0.1 to 1.7) 5.2 (4.6 to 5.9) 1.3 (0.5 to 3.4) 8.2 (5.8 to 11.5) 
 Tremor Primidone  0.3 (0.1 to 0.5) 0.3 (0.1 to 1.9) 0.3 (0.1 to 1.6) 
 Alcohol withdrawal Carbamazepine  0.2 (0.1 to 0.3)  0.6 (0.2 to 2.0) 
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Exposure rates and prevalence of mental illness 
The group of people covered by the study was intended to be as close as we could get 
to a general population group. This means we would expect that the rates of use of 
drugs intended for the treatment of mental illness would be lower than those reported in 
groups of people with learning disability under treatment by mental health services. The 
group would be expected to have an overall pattern of mental health problems more 
similar to that found in the general population in population-based studies of psychiatric 
morbidity.35 However inevitably the group will not be a true reflection of all people with 
learning disability or autism in the population since we had no way of identifying those 
not already identified as such by their GP.   
 
The research study likely to give the closest approximation of the expected patterns of 
psychiatric morbidity for adults with learning disabilities in our study sample is by 
Cooper and her colleagues.36 Cooper studied as far as possible all adults with a 
learning disability living in a part of Scotland. She used a multiple key informant strategy 
(including the local authority, social care providers, GPs and secondary health care 
services) to identify all people aged 16 and older with learning disabilities in the Greater 
Glasgow Health Board area in 2002-4. She used four different sets of diagnostic 
protocols for mental illness to clarify the effect of using different definitional protocols on 
the number of individuals identified as having diagnosable problems. The approach 
most appropriate for comparison with the present prescribing data would be the clinical 
diagnosis made by the psychiatrist who, in Cooper’s study, had undertaken a 
comprehensive standardised assessment. This gave substantially higher rates of 
mental illness than major diagnostic classifications applied algorithmically to responses 
to standardised interview schedules. Cooper included both problem behaviour and 
autism in the broad range of what she termed ‘mental ill health’. On this basis, in her 
initial prevalence survey, 40.9% of people with learning disabilities had some type of 
mental ill health. The prevalence of psychotic disorder was 4.4%, affective disorder 
6.6%, anxiety disorder 3.8% and sleep disorder 0.6%. Additionally, 7.5% had an autistic 
spectrum disorder and 22.5% were considered to show some type of problem 
behaviour. Overall, 22.4% had some type of mental ill health not including problem 
behaviour and autistic spectrum conditions, and 37% had some type of mental ill health 
including problem behaviour but not including autism alone. It is worth noting that these 
observed rates are likely to have been higher than would have been known to GPs 
before the study since the screening process itself may have identified problems not 
previously reported to them.  
 
It is also likely that these rates would be higher than the rates in the population we 
studied for three reasons. First Greater Glasgow is an area of high overall deprivation, 
whereas England as a whole should be average in this respect; high rates of deprivation 
are usually associated with higher rates of mental illnesses of most types. Second the 
key informant strategy used for Cooper’s study identified a population prevalence of 
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learning disability of only 0.33%. This suggests it was less effective at identifying this 
than current English GP registers which, at the time to which our data relate, identified 
0.46% of people as having learning disabilities. Generally those with more severe 
disabilities or more associated problems would be more visible. Third, Coopers study 
included people currently in psychiatric hospitals. In England, at any point in time, about 
1.5% of adults with learning disabilities are in psychiatric hospitals.37 At the census of 
2014, 1,365 of these people were considered to need hospitalisation primarily because 
of a mental illness, not a behaviour disorder or other perceived risk. This suggests that if 
Cooper’s overall prevalence of psychotic illness (4.4%) had applied exactly in England 
at the time to which our data relate, the prevalence outside hospital would have been 
3.8%.  
 
On this basis, the numbers prescribed psychotropic medication in the data we looked at 
substantially exceeded the numbers likely to have the types of mental illness for which 
these drugs are primarily indicated. A rough estimate would be that the prescribing rate 
for antipsychotics to adults with learning disabilities is almost four times the probable 
rate of psychosis, for hypnotics more than four times the rate of sleep disorders, but for 
anxiolytics reasonably close to the rate of anxiety states. We cannot make such a neat 
comparison for antidepressants and for drugs used for mania and hypomania as 
Cooper provides a single rate for affective disorders and we did not include drugs used 
for mania and hypomania in our analysis of people receiving drugs from multiple BNF 
sections. However at 6.6%, the likely rate of all affective disorders is only two fifths of 
the rate of antidepressant prescribing and similar to the rate of prescribing of drugs in 
the category of those used for mania and hypomania. This comparison suggests that 
most of the prescribing, at least of antipsychotics and antidepressants, is for reasons 
other than current psychosis or affective disorders. Some, of course may be to prevent 
relapses in people who have had prior episodes of depression or psychosis.  
 
The population based nature of our study, taken with Coopers estimates of the 
prevalence of mental illness allows some estimation of the scale of this usage 
nationally. The population of adults with learning disabilities known to their GP in 
England, of whom our study was representative, in the three years of the study 
averaged 188,920. The figures above suggest that 23,800 (13%) of these would have 
been being treated with antipsychotics in the absence of psychosis, 19,500 (10%) with 
antidepressants in the absence of a relevant affective disorder and 4,000 (2%) with a 
hypnotic in the absence of a sleep disorder. These numbers would have overlapped 
substantially. Our overlap analysis showed that in adults with learning disabilities 
roughly 40% of those prescribed antipsychotics were also prescribed antidepressants, 
and the proportion of those prescribed antidepressants also prescribed antipsychotics 
was similar. On this basis it seems reasonable to estimate that between 30,000 and 
35,000 adults with learning disabilities nationally are likely to be being prescribed an 
antidepressant or an antipsychotic without the key indications for doing so.   
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Rates of mental illness in the population of children with intellectual disabilities have 
been reported by Emerson and Hatton using data from the first two British child 
psychiatric morbidity surveys.38 They noted 36% had some type of psychiatric disorder 
(4.5 times the rate in children without intellectual disabilities), 11.4% (3.6 times) an 
anxiety disorder including 1.6% (2.7 times) generalised anxiety disorder, 1.4% (1.6 
times) depression, 8.3% (9.2 times) hyperkinesis (ADHD), 20.5% (4.8 times) a conduct 
disorder and 8% (26.7 times) an autistic spectrum condition. 4.4% (5.5 times) had both 
and emotional disorder and a conduct disorder.    However their analysis was based on 
identifying 3.5% of children as having learning disabilities, a prevalence similar to that 
found in schools but substantially more inclusive than our effective operational criterion 
of being recognised as having a learning disability by the GP. As noted above, in our 
data, GPs appear to have identified 0.35% of children and young people as having 
learning disabilities. This is close to but slightly lower than the prevalence identified by 
GPs in adults. Hence prevalence figures for mental illness within the group identified by 
Emerson and Hatton are not directly comparable with what might be expected in the 
much narrower group identified by their GP. It seems likely that those identified by their 
GP will be those with more physical problems. But whether this means they would have 
more mental health problems is not clear.  
 
In comparison to these rates of likely illness, and in light of the clearer evidence in 
relation to use of risperidone in behavioural disturbance in children with autism cited in 
the introduction, it is harder to be clear that the much smaller rates of prescribing seen 
for children and adolescents were substantially disproportionate.   
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Discussion 
The study arose from the concerns, reported in Transforming Care, that antipsychotic 
and antidepressant medicines were being overused in the care of people with learning 
disabilities and autism. The study described the use of four classes of psychotropic 
drugs among people with learning disabilities or autism who are not currently in hospital.  
 
Key findings 
The numbers of relevant patients identified (17,887 people with learning disabilities and 
an additional 11,136 with autism) suggested that the database covers about 7.8% of the 
relevant English population. People with learning disabilities covered the age spectrum, 
those identified as having autism alone were predominantly (77%) aged under 18. 
 
People with learning disabilities:  
Patients were exposed to one or more of the drugs we studied on 41.3% of person days 
for adults and 14.7% for children and young people. Excluding antiepileptics, the figures 
were 29.5% of adult- and 6.8% of children and young people’s person-time. 
Antipsychotic drugs were being prescribed on 17.0% of adult and 2.4% of children and 
young people’s person-days, drugs used in mania and hypomania on 7.1% and 0.3% 
respectively, antidepressants on 16.9% and 1.2%, anxiolytics on 4.2% and 0.6% and 
antiepileptic drugs on 22.9% and 10.2%. Hypnotics were the only group of drugs we 
studied for which a higher proportion of children and young people’s time was exposed 
(children and young people 4.1% of person-days; adults 2.7%). For most groups of 
drugs, exposure rates rose through adult life. The rate of prescribing antipsychotics in 
people aged 65 and over was 2.9 times the rate in those aged 18 to 24; corresponding 
multiples were 1.8 for hypnotics, 2.9 for anxiolytics, 2.5 for drugs used in mania and 
hypomania and 2.7 for antidepressants. The multiple for antiepileptics, 1.2, was much 
lower.  
 
People with autism:  
For people with autism but not learning disabilities, the rates we can report for children 
were based on large numbers and therefore probably reflect the experience of people 
with autism in the population reasonably well. Adult rates were based on much smaller 
numbers of individuals. Interpretting adult rates therefore requires some allowance for 
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the question which individuals had their autism identified and recorded by their GP.  It is 
likely that this would be a particularly disabled group, not representative of adults with 
autism in the population generally. Among those aged under 18, 1.5% of person days 
were exposed to prescribing of antipsychotics, 0.2% drugs for the management of 
mania and hypomania, 1.1% antidepressants, 3.2% hypnotics, 0.1% anxiolytics and 
2.0% anti-epileptics. Corresponding rates for adults with autism were: antipsychotics 
8.2%, drugs for the management of mania and hypomania 3.5%, antidepressants 
17.0%, hypnotics 2.1%, anxiolytics 1.8% and anti-epileptics 6.9%. 
 
Patterns of prescribing:  
A large proportion (90% or more) of the prescribing of drugs in most of the BNF sections 
and sub-sections we studied was not short term: the first visible prescription was 
followed by at least one repeat prescription. The only exceptions to this appeared to be 
anxiolytics, and, for acults with autism, hypnotics. However even for these groups the 
majority of periods of prescribing involved more than a single prescription.  Strikingly, 
hypnotic prescribing involved at least one repeat prescription in 96.0% of cases despite 
the BNF guidance that chronic insomnia is rarely benefitted by hypnotics and may be a 
consequence of long term hypnotic use.  
 
Prescribing of more than one drug within BNF a sub-section was seen for adults with 
learning disabilities in 22.5% of prescriptions for antipsychotic drugs, 10.8% for 
antidepressants and 43.3% for antiepileptics, though in the latter case there may be 
good therapeutic reasons. As explained in the previous section, in the case of 
antipsychotics this may be a slight underestimate as a consequence of depot injectable 
preparations of antipsychotics being grouped in a separate BNF sub-section from other 
preparations. Simultaneous prescribing of drugs from more than one of the five BNF 
(sub)-sections we studied in more detail was also common.  Two in five adults (39.9%) 
and 17.6% of all children and young people with learning disabilities who were receiving 
any of the drugs were receiving drugs from two or more groups. Corresponding 
proportions for people with autism but not learning disabilities were 30.3% for adults and 
13.6% for children and young people.  
  
Relatively little prescribing was reported to be at doses above BNF recommended limits.  
For antipsychotics, 5.5% of prescriptions for adults with learning disabilities and 5.6% 
for adults with autism were for doses above recommended limits, The corresponding 
proportion for prescriptions of hypnotics and anxiolytics for adults with learning 
disabilities was 2.4%. High dose rates were seen for roughly double these proportions 
in the youngest adult age group. In all other cases high doses were recorded in fewer 
than 2% of prescriptions. However in 27.1% of prescriptions overall, the dose was not 
sufficiently clearly recorded for analysis. Our analysis also did not consider additive 
dose effects in patients prescribed more than one drug in a BNF section or sub-section.  
Prescribing of psychotropic drugs to people with learning disabilities 
46 
 
The proportions of patients for whom licensed indications were recorded for the drugs 
received varied and was difficult to interpret. Amongst adults with learning disabilities, 
41.9% of those prescribed antipsychotics, 68.2% prescribed antidepressants, 44.1% 
prescribed hypnotics and 53.6% prescribed anxiolytics had relevant indications 
recorded in their notes. A much higher proportion of those receiving anti-epileptics 
(90.7%) had records of relevant indications. These patterns were broadly reflected for 
other groups except that relevant indications were less often recorded for children and 
young people in relation to hypnotics, anxiolytics and antipsychotics. 
 
Comparison with epidemiological studies of mental illness in adults with learning 
disabilities suggests that 13% of the population (roughly 23,800 people) are being 
prescribed antipsychotics in the absence of a psychotic illness, and 10% 
antidepressants in the absence of an affective illness (roughly 19,500 people).  Allowing 
for overlap, which is common, we estimate that between 30,000 and 35,000 adults with 
a learning disability in England are taking one or both of these types of drug in the 
absence of the conditions for which they are indicated. Perhaps the single clearest 
impression given by the data is the way that the load of medication given to adults with 
learning disabilities appears to accumulate through their adult life. It seems that new 
drugs are added to address newly emerging problems, but they are seldom removed 
when the problem changes or the likely efficacy of the drug wanes. 
 
 
Reliability and limitations 
The Clinical Practice Research Datalink is a well-established research service. There is 
no good reason to doubt that the primary care data it holds provides a reasonable 
representation of the state of care provided in general practice across England. 
Identification of patients with learning disabilities is likely to have been more reliable 
than that of patients with autism, though both are clearly far from complete. The 
introduction of learning disabilities registers in 2006 under the Quality and Outcomes 
Framework has provided a clear set of codes by which this group of patients should be 
identifiable in GP note systems. Registration of patients with learning disabilities has 
been required under this programme since then. The reason for believing that 
registration is incomplete is that the overall prevalence figures (0.45% of adults at the 
time to which the study data relate) is substantially lower than the prevalence found in 
school age populations.39 However it is similar to prevalence figures found in areas of 
the country where there have been case registers for research and planning purposes 
for many years.40 Whilst this is likely to be only about a quarter of the people who have 
a learning disability it probably represents all or most of those whose make use of 
statutory services for this type of disability or whose disability has been recognised by 
their GP. It probably includes almost all with severe or profound learning disability as 
well as those with the most obvious causes such as Down’s syndrome. Autism, like 
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learning disability is a persistent condition in the sense that whilst some people with 
autism develop ways of accommodating to the extent that the consequent disability is 
reduced, it does not remit. For people with autism the extent of under-diagnosis in 
adults was evident from the very sharp fall in identified prevalence with increasing age. 
We have noted the likely effect of this in identifying adults, particularly older adults with 
autism who were a more narrowly selected group, probably on average much more 
disabled than the much larger group of people with autism identified in our sample in 
childhood. In both cases, our view is that we have identified most of those in the 
practices covered by CPRD GOLD whose GPs were aware of their learning disability or 
autism.    
 
The data on which we are reporting cover patients permanently registered with a GP. 
We have excluded individuals only temporarily registered. The scope of the data we 
used should have included all of those not currently in hospital. By linkage to NHS 
Hospital Episode Statistics we attempted to exclude periods for individuals when they 
were in hospital and consequently when prescribing would not have been undertaken or 
recorded by their GP. However this would not have identified periods when individuals 
were in private mental hospitals. For these periods we would not have seen any 
prescribing. This should not have had an important effect as the numbers involved 
would probably have been less than 1% of the person years we were studying.  
The patients in the study would have included all patients living independently, and also 
those living in residential care homes, group homes, or other supported or congregate 
setting as long as they was not classified as hospitals. GPs generally do not prescribe 
drugs for people in hospitals, whether these are run by the NHS or independent sector 
organisations. We are aware that there may be a small number of exceptions to this in 
some private hospitals, however we think this is unlikely to have produced substantial 
distortion.  
 
The study should have covered all GP prescriptions for included patients. However it 
would not have captured prescriptions given by secondary care-based specialists for 
patients living in the community. Generally specialists do not do this. They determine 
the most appropriate medication and then ask patients’ GPs to prescribe this for them. 
The most obvious gap in our data which would have arisen from this would be the 
period after patients leave hospital when they are given a supply of drugs for a few days 
to take home with them. These supplies last only a few days so this should not be 
important. However it could also explain the very low apparent rate of use of depot 
antipsychotics if these are prescribed, dispensed and administered by community-
based secondary care staff. In 2006, Bramble reported unwillingness on the part of GPs 
at that time to prescribe expensive medications (notably risperidone and melatonin) in 
the long term. This could still be an issue for prescribing of melatonin, but the 
antipsychotic drugs which were expensive at that time have all subsequently come out 
of patient so non-proprietary makes should be available at modest prices.    
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It is less clear how completely GP’s record other information such as diagnoses or 
symptoms. It is possible that busy GP’s could record a prescription, for example for an 
antidepressant, as shorthand covering both the symptoms presented and the 
management chosen. This would be poor note keeping but it would have appeared to 
our analysis as a prescription without a clinical indication.  
 
We have no way of telling to what extent patients actually took the prescribed 
medication. It is likely that most of the patients identified in the study would have had a 
substantial amount of support either from family members or paid carers. Probably 
relatively few of the patients would have taken the initiative themselves to seek initial or 
continuing treatment. It is likely that carers would have been influential both in arranging 
consultations and in procuring and administering medication. So the compliance 
question would have related to carers at least as much as to the patients.  
    
We noted the limitations of the data in the analysis of the frequency of use of high 
doses; data were missing or uninterpretable in more than a quarter of cases. We also 
did not estimate cumulative high doses where individuals were prescribed more than 
one compound in a BNF section or sub-section. 
 
Finally, there were limitations to the extent we could explore variation around the 
country. The source we used can be reported at regional level, but the differences of 
interest would be more between local services than overall regions.  
 
 
Usage of drugs 
In addition to overall prescribing in relation to diagnoses, we were able to report on 
three aspects of drug usage: dosage, chronicity and poly-pharmacy. Our findings about 
the use of antipsychotics can be compared to those of the Royal College of 
Psychiatrists’ Prescribing Observatory for Mental Health study described above, 
although it should be noted that they were describing patients receiving secondary care 
who might be expected to have more severe problems, and thus be receiving more 
medication than the overall population of people with learning disabilities. This group 
only considered adults with learning disabilities, so our comparisons are with that group 
in our data.   
 
Paton’s reported that the proportion of patients on antipsychotic medication where 
doses exceeded recommended limits ranged from 4% to 17% between participating 
centres. However she did not report findings for specific age groups. Overall we found 
that 4.5% of antipsychotic prescriptions for adults with learning disabilities were 
definitely at doses above BNF recommended limits. It was also notable that the figure 
for the youngest group of adults was twice as high. However our findings on this were 
incomplete (as described above) because of the high proportion of prescriptions for 
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which we did not have usable data and the fact that we were not able to calculate total 
dose equivalents where multiple compounds were used.  
 
Paton reported that 73% of adults with learning disabilities currently prescribed 
antipsychotics were also taking other classes of medication for mental illness, 
behavioural problems or epilepsy. The corresponding proportion in our study was 
67.3%. She reported that 33% were also taking antidepressants. We found this in 
40.0% of adults with learning disabilities and 47.1% with autism but not a learning 
disability. It is not easy to compare other drug categories since Paton grouped them 
differently, but she reported that 15% were also taking a benzodiazepine. In our figures, 
18.9% of adults with learning disabilities who were taking antipsychotics were also 
taking either a hypnotic or an anxiolytic.  
 
Use of more than one antipsychotic is less easy to compare.  Paton gave an overall 
figure of 15% for the proportion of sample patients (selected for receiving an 
antipsychotic) who were prescribed more than one. The corresponding figure for adults 
with learning disabilities in our data was 22.5%.  
Compared to rates of use in the general population, the rate of prescribing of 
antipsychotics in people with learning disabilities is very high. Marston and her 
colleagues reported this in a comparable study using a similar general practice 
database (THIN).41 They found the rate for people aged under 18 to be 63 per 100,000.  
 
The reported prescribing rates we found for children and young people were 38 times 
that figure for those with learning disabilities and 24 times for people with autism. A 
rough estimation suggests that patients with learning disabilities and/or autism could 
account for about 40% of antipsychotics prescribed by GPs to children and young 
people. Unfortunately, the age banding Marston used for adults was different to the one 
we adopted. So precise comparisons are not possible. However antipsychotic 
prescribing for people with learning disabilities was roughly 18 times as common as for 
the general population up to age 45 and in excess of 30 times as common for older 
people. For adults with autism the prescribing rate was roughly 10 times that in the 
general population.   
 
Further refinements, future work 
This was an initial study. The study demonstrated that the Clinical Practice Research 
Datalink primary care database is effective for monitoring use of psychotropic drugs in 
people with learning disabilities. It is effective also in children with autism, although the 
numbers suggest it may be over-inclusive in this group. Adults with autism are clearly 
very much less fully identified, making interpretation of the data about them harder. This 
source would be an effective tool for monitoring national trends. CPRD itself currently 
monitors only about 8% of the UK population, but has plans to double this proportion by 
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April 2016 by including data from a range of GP software systems. Increased coverage 
would increase confidence in the results of research and monitoring conducted. Other 
research databases are available which bring the total covered up to about 20%. 
Coverage of the different monitoring systems varies regionally around England. Hence 
ideally a monitoring system should use all of them. 
 
If a monitoring programme were to be established, the queries we used could be 
enhanced in a number of ways. The coverage of high dose prescribing could be 
improved at least to the extent of calculating combined dose equivalents where multiple 
agents have been used. The monitoring of clinical indications could be sharpened by 
exploring the plausibility of possible indications such as persistent vomiting or allergic 
phenomena for the use of specific phenothiazines in more detail for individuals where 
the question was relevant. We accepted a single reference to these symptoms as 
sufficient to qualify as an indication. In practice this type of medication is not a first line 
treatment for either indication and would only be likely to be prescribed for this reason if 
the symptoms were persistent, failed to respond to simpler approaches and probably in 
the context of other major illness. Algorithms to assess these could be developed.   
Side effects are a major concern in prescribing many psychotropics. In monitoring their 
use through data abstracted through GP record systems it should be possible to check 
the extent of coverage of recommended monitoring procedures and also the patterns of 
response to emerging adverse trends in weight, plasma cholesterol and triglyceride 
levels or neurological extrapyramidal side effects. 
 
Duration of treatment is important in the use of hypnotics and anxiolytics where 
habituation means that long term treatment is likely to be ineffective and may even be 
counterproductive. The two recognised uses of risperidone in relation to behaviour 
(persistent aggression in conduct disorder and in moderate to severe Alzheimer’s 
disease) are also specifically recognised as being appropriate only in the short term (up 
to six weeks).  A continuing programme of monitoring drug use through extracts from 
GP record systems could usefully examine durations of treatment in more detail and 
over longer time frames for these and other drugs.        
 
Conclusion 
The study shows antipsychotic and antidepressant drugs are being prescribed for 
people with learning disabilities in England in the absence of the conditions for which 
they are known to be effective. This is in line with the findings from previous studies. 
The two contributions this study makes are first that it establishes the scale and patterns 
of prescribing and second that it demonstrates that the CPRD primary care database 
documents it well. The approach used in this paper, with reasonably straightforward 
enhancements would thus provide a useful method of monitoring the progress of 
attempts to tackle this problem.     
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Annexes 
Annex table 1. Proportion (percentages) of person years exposed to one or more drugs in the group by age sex and disability category. (95% 
confidence intervals in parantheses) 
BNF Group / sub group 
and Age group  
Learning disabilities   Autism without learning disabilities 
Female Male Persons Female Male Persons 
4.1. All Hypnotics and 
anxiolytics 
  
  
   
 
Age <18 4.0 (3.3 to 4.9) 4.9 (4.3 to 5.6) 4.6 (4.2 to 5.1) 4.2 (3.6 to 4.9) 3.1 (2.9 to 3.4) 3.3 (3.1 to 3.6) 
 
Age 18-24 3.2 (2.5 to 4.0) 3.8 (3.3 to 4.5) 3.6 (3.1 to 4.1) 3.5 (2.2 to 5.5) 1.9 (1.4 to 2.5) 2.2 (1.7 to 2.7) 
 
Age 25-44 5.3 (4.8 to 5.9) 6.3 (5.8 to 6.9) 5.9 (5.5 to 6.3) 6.1 (4.1 to 8.8) 4.4 (3.5 to 5.7) 4.8 (3.9 to 5.9) 
 
Age 45-64 8.9 (8.2 to 9.7) 7.9 (7.3 to 8.6) 8.4 (7.9 to 8.9) 6.6 (3.7 to 11.5) 5.9 (4.1 to 8.5) 6.1 (4.5 to 8.3) 
 
Age 65+ 9.8 (8.3 to 11.5) 7.5 (6.3 to 9.0) 8.7 (7.7 to 9.8) 4.5 (0.8 to 21.8) 8.5 (3.7 to 18.4) 7.4 (3.4 to 15.2) 
 
All ages 6.3 (6.0 to 6.7) 6.1 (5.8 to 6.5) 6.2 (6.0 to 6.5) 4.4 (3.8 to 5.0) 3.1 (2.9 to 3.4) 3.4 (3.2 to 3.6) 
4.1.1. Hypnotics 
  
  
   
 
Age <18 3.6 (2.9 to 4.3) 4.4 (3.9 to 5.1) 4.1 (3.7 to 4.6) 3.9 (3.4 to 4.6) 3.1 (2.8 to 3.4) 3.2 (3.0 to 3.5) 
 
Age 18-24 1.6 (1.1 to 2.2) 2.2 (1.7 to 2.7) 2.0 (1.6 to 2.4) 2.5 (1.5 to 4.3) 1.3 (0.9 to 1.9) 1.5 (1.2 to 2.1) 
 
Age 25-44 2.2 (1.8 to 2.6) 2.2 (1.9 to 2.6) 2.2 (2.0 to 2.5) 2.4 (1.3 to 4.4) 2.4 (1.7 to 3.4) 2.4 (1.8 to 3.3) 
 
Age 45-64 4.1 (3.6 to 4.7) 3.1 (2.7 to 3.6) 3.6 (3.2 to 3.9) 5.4 (2.9 to 10.0) 2.9 (1.7 to 4.8) 3.5 (2.3 to 5.3) 
 
Age 65+ 3.9 (3.0 to 5.1) 3.2 (2.4 to 4.3) 3.5 (2.9 to 4.3) 4.5 (0.8 to 21.8) 6.8 (2.7 to 16.2) 6.2 (2.7 to 13.6) 
 
All ages 3.0 (2.8 to 3.3) 3.0 (2.7 to 3.2) 3.0 (2.8 to 3.1) 3.7 (3.2 to 4.3) 2.9 (2.6 to 3.1) 3.0 (2.8 to 3.2) 
4.1.2. Anxiolytics 
  
  
   
 
Age <18 0.5 (0.3 to 0.8) 0.7 (0.5 to 1.0) 0.6 (0.5 to 0.8) 0.3 (0.1 to 0.5) 0.0 (0.0 to 0.1) 0.1 (0.1 to 0.1) 
 
Age 18-24 1.7 (1.2 to 2.3) 1.9 (1.5 to 2.4) 1.8 (1.5 to 2.2) 1.0 (0.4 to 2.3) 0.7 (0.4 to 1.1) 0.7 (0.5 to 1.1) 
 
Age 25-44 3.4 (3.0 to 3.9) 4.4 (3.9 to 4.8) 3.9 (3.6 to 4.3) 3.9 (2.4 to 6.2) 2.8 (2.0 to 3.8) 3.1 (2.3 to 4.0) 
 
Age 45-64 5.5 (5.0 to 6.2) 5.4 (4.9 to 6.0) 5.5 (5.1 to 5.9) 2.4 (0.9 to 6.0) 3.3 (2.0 to 5.4) 3.1 (2.0 to 4.7) 
 
Age 65+ 6.1 (5.0 to 7.5) 4.5 (3.6 to 5.8) 5.3 (4.5 to 6.2) 0.0 (0.0 to 14.9) 3.4 (0.9 to 11.5) 2.5 (0.7 to 8.6) 
 
All ages 3.6 (3.4 to 3.9) 3.5 (3.3 to 3.8) 3.6 (3.4 to 3.8) 0.7 (0.5 to 1.0) 0.4 (0.3 to 0.5) 0.4 (0.4 to 0.5) 
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BNF Group / sub group 
and Age group  
Learning disabilities   Autism without learning disabilities 
Female Male Persons Female Male Persons 
4.2. All Antipsychotics 
  
  
   
 
Age <18 1.8 (1.4 to 2.4) 3.1 (2.6 to 3.6) 2.6 (2.3 to 3.0) 1.7 (1.3 to 2.2) 1.6 (1.4 to 1.7) 1.6 (1.4 to 1.8) 
 
Age 18-24 9.0 (7.9 to 10.3) 10.3 (9.4 to 11.4) 9.8 (9.1 to 10.6) 7.8 (5.8 to 10.4) 6.1 (5.2 to 7.1) 6.4 (5.6 to 7.3) 
 
Age 25-44 14.2 (13.3 to 15.1) 20.0 (19.1 to 20.9) 17.4 (16.7 to 18.0) 15.5 (12.4 to 19.3) 10.8 (9.2 to 12.5) 11.9 (10.5 to 13.5) 
 
Age 45-64 24.2 (23.0 to 25.3) 25.9 (24.8 to 27.0) 25.1 (24.3 to 25.9) 8.4 (5.1 to 13.7) 16.4 (13.3 to 20.1) 14.3 (11.8 to 17.3) 
 
Age 65+ 29.4 (27.0 to 31.8) 28.2 (25.9 to 30.6) 28.8 (27.1 to 30.5) 0.0 (0.0 to 14.9) 11.9 (5.9 to 22.5) 8.6 (4.2 to 16.8) 
 
All ages 16.0 (15.5 to 16.5) 17.1 (16.7 to 17.6) 16.6 (16.3 to 17.0) 3.7 (3.2 to 4.3) 3.0 (2.8 to 3.2) 3.1 (2.9 to 3.3) 
4.2.1. Antipsychotic drugs 
  
  
   
 
Age <18 1.4 (1.0 to 1.9) 2.9 (2.4 to 3.4) 2.4 (2.0 to 2.7) 1.6 (1.2 to 2.0) 1.4 (1.3 to 1.6) 1.5 (1.3 to 1.6) 
 
Age 18-24 7.0 (6.0 to 8.2) 8.7 (7.8 to 9.7) 8.1 (7.4 to 8.8) 6.4 (4.6 to 8.9) 5.1 (4.3 to 6.1) 5.4 (4.6 to 6.2) 
 
Age 25-44 11.5 (10.7 to 12.3) 16.7 (15.9 to 17.5) 14.3 (13.8 to 14.9) 13.6 (10.6 to 17.2) 10.6 (9.0 to 12.3) 11.3 (9.9 to 12.8) 
 
Age 45-64 21.0 (19.9 to 22.1) 23.2 (22.2 to 24.3) 22.2 (21.4 to 23.0) 6.6 (3.7 to 11.5) 14.5 (11.5 to 18.0) 12.4 (10.0 to 15.2) 
 
Age 65+ 27.1 (24.8 to 29.6) 26.4 (24.1 to 28.7) 26.7 (25.1 to 28.4) 0.0 (0.0 to 14.9) 11.9 (5.9 to 22.5) 8.6 (4.2 to 16.8) 
 
All ages 13.6 (13.1 to 14.1) 15.0 (14.5 to 15.4) 14.4 (14.0 to 14.7) 3.3 (2.8 to 3.8) 2.7 (2.5 to 2.9) 2.8 (2.6 to 3.0) 
4.2.2. Antipsychotic depot 
injections 
  
  
   
 
Age <18 0.0 (0.0 to 0.2) 0.0 (0.0 to 0.1) 0.0 (0.0 to 0.1) 0.0 (0.0 to 0.1) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 
 
Age 18-24 0.0 (0.0 to 0.2) 0.0 (0.0 to 0.1) 0.0 (0.0 to 0.1) 0.0 (0.0 to 0.7) 0.0 (0.0 to 0.2) 0.0 (0.0 to 0.1) 
 
Age 25-44 0.1 (0.0 to 0.2) 0.2 (0.1 to 0.3) 0.1 (0.1 to 0.2) 0.0 (0.0 to 0.9) 0.1 (0.0 to 0.5) 0.1 (0.0 to 0.4) 
 
Age 45-64 0.5 (0.4 to 0.8) 0.2 (0.1 to 0.3) 0.4 (0.3 to 0.5) 0.0 (0.0 to 2.3) 0.0 (0.0 to 0.8) 0.0 (0.0 to 0.6) 
 
Age 65+ 1.3 (0.8 to 2.0) 0.6 (0.3 to 1.1) 0.9 (0.6 to 1.3) 0.0 (0.0 to 14.9) 0.0 (0.0 to 6.1) 0.0 (0.0 to 4.5) 
 
All ages 0.3 (0.2 to 0.4) 0.2 (0.1 to 0.2) 0.2 (0.2 to 0.3) 0.0 (0.0 to 0.1) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 
4.2.3. Drugs used for 
mania and hypomania 
  
  
   
 
Age <18 0.4 (0.2 to 0.7) 0.2 (0.1 to 0.4) 0.3 (0.2 to 0.4) 0.2 (0.1 to 0.4) 0.2 (0.1 to 0.2) 0.2 (0.1 to 0.2) 
 
Age 18-24 3.2 (2.5 to 4.1) 3.1 (2.5 to 3.7) 3.1 (2.7 to 3.6) 2.7 (1.6 to 4.5) 2.0 (1.5 to 2.7) 2.2 (1.7 to 2.7) 
 
Age 25-44 5.9 (5.4 to 6.5) 7.7 (7.1 to 8.3) 6.9 (6.5 to 7.3) 5.8 (3.9 to 8.5) 4.0 (3.1 to 5.2) 4.4 (3.6 to 5.5) 
 
Age 45-64 8.3 (7.5 to 9.0) 9.9 (9.2 to 10.7) 9.1 (8.6 to 9.7) 7.8 (4.6 to 12.9) 7.5 (5.4 to 10.2) 7.6 (5.7 to 9.9) 
 
Age 65+ 8.8 (7.4 to 10.4) 7.0 (5.7 to 8.4) 7.9 (6.9 to 8.9) 0.0 (0.0 to 14.9) 0.0 (0.0 to 6.1) 0.0 (0.0 to 4.5) 
 
All ages 5.7 (5.4 to 6.1) 6.0 (5.7 to 6.3) 5.9 (5.7 to 6.1) 1.2 (0.9 to 1.5) 0.8 (0.7 to 0.9) 0.8 (0.7 to 1.0) 
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BNF Group / sub group 
and Age group  
Learning disabilities   Autism without learning disabilities 
Female Male Persons Female Male Persons 
4.3. All Antidepressants 
  
  
   
 
Age <18 1.2 (0.8 to 1.7) 1.2 (0.9 to 1.6) 1.2 (1.0 to 1.5) 1.8 (1.4 to 2.3) 1.0 (0.9 to 1.2) 1.1 (1.0 to 1.3) 
 
Age 18-24 9.9 (8.7 to 11.2) 6.9 (6.1 to 7.8) 8.0 (7.3 to 8.7) 16.6 (13.6 to 20.0) 8.0 (7.0 to 9.2) 9.5 (8.5 to 10.6) 
 
Age 25-44 18.0 (17.1 to 19.0) 14.2 (13.4 to 15.0) 15.9 (15.3 to 16.5) 31.6 (27.3 to 36.2) 22.5 (20.4 to 24.8) 24.6 (22.7 to 26.7) 
 
Age 45-64 25.0 (23.9 to 26.2) 18.2 (17.2 to 19.2) 21.4 (20.6 to 22.1) 32.5 (25.9 to 40.0) 28.7 (24.8 to 33.0) 29.7 (26.3 to 33.5) 
 
Age 65+ 24.0 (21.8 to 26.4) 18.6 (16.7 to 20.7) 21.3 (19.8 to 22.8) 31.8 (16.4 to 52.7) 22.0 (13.4 to 34.1) 24.7 (16.6 to 35.1) 
 
All ages 17.2 (16.7 to 17.8) 11.8 (11.4 to 12.2) 14.1 (13.8 to 14.5) 7.0 (6.3 to 7.7) 3.8 (3.5 to 4.0) 4.4 (4.1 to 4.6) 
4.3.1. Tricyclic and related 
antidepressant drugs 
  
  
   
 
Age <18 0.0 (0.0 to 0.2) 0.1 (0.1 to 0.3) 0.1 (0.0 to 0.2) 0.1 (0.0 to 0.3) 0.1 (0.1 to 0.2) 0.1 (0.1 to 0.2) 
 
Age 18-24 1.4 (1.0 to 2.0) 0.6 (0.4 to 0.9) 0.9 (0.7 to 1.2) 1.9 (1.1 to 3.6) 0.7 (0.4 to 1.1) 0.9 (0.6 to 1.3) 
 
Age 25-44 3.0 (2.6 to 3.5) 2.1 (1.8 to 2.5) 2.5 (2.3 to 2.8) 5.3 (3.6 to 8.0) 2.9 (2.1 to 3.9) 3.5 (2.7 to 4.4) 
 
Age 45-64 5.8 (5.2 to 6.5) 3.3 (2.9 to 3.8) 4.5 (4.1 to 4.9) 10.8 (7.0 to 16.5) 5.0 (3.4 to 7.5) 6.6 (4.9 to 8.8) 
 
Age 65+ 7.4 (6.2 to 9.0) 5.8 (4.7 to 7.2) 6.6 (5.8 to 7.6) 0.0 (0.0 to 14.9) 1.7 (0.3 to 9.0) 1.2 (0.2 to 6.7) 
 
All ages 3.6 (3.3 to 3.9) 2.0 (1.8 to 2.2) 2.7 (2.5 to 2.9) 1.1 (0.8 to 1.4) 0.5 (0.4 to 0.5) 0.6 (0.5 to 0.7) 
4.3.3. Selective serotonin 
re-uptake inhibitors 
  
  
   
 
Age <18 1.2 (0.8 to 1.7) 1.1 (0.8 to 1.4) 1.1 (0.9 to 1.4) 1.7 (1.3 to 2.1) 0.9 (0.8 to 1.1) 1.0 (0.9 to 1.2) 
 
Age 18-24 8.1 (7.0 to 9.3) 5.4 (4.7 to 6.2) 6.4 (5.8 to 7.1) 12.9 (10.2 to 16.0) 6.1 (5.2 to 7.2) 7.3 (6.4 to 8.3) 
 
Age 25-44 13.6 (12.8 to 14.5) 9.7 (9.1 to 10.4) 11.5 (11.0 to 12.0) 22.1 (18.3 to 26.3) 16.1 (14.2 to 18.1) 17.5 (15.8 to 19.3) 
 
Age 45-64 16.6 (15.6 to 17.6) 12.6 (11.8 to 13.4) 14.5 (13.8 to 15.1) 22.3 (16.6 to 29.2) 20.2 (16.7 to 24.1) 20.7 (17.7 to 24.1) 
 
Age 65+ 13.1 (11.4 to 15.0) 10.9 (9.4 to 12.6) 11.9 (10.8 to 13.2) 18.2 (7.3 to 38.5) 20.3 (12.0 to 32.3) 19.8 (12.5 to 29.7) 
 
All ages 12.1 (11.6 to 12.5) 8.1 (7.8 to 8.5) 9.8 (9.5 to 10.1) 5.3 (4.7 to 6.0) 2.9 (2.7 to 3.1) 3.3 (3.1 to 3.6) 
4.3.4. Other 
antidepressant drugs 
  
  
   
 
Age <18 0.0 (0.0 to 0.2) 0.0 (0.0 to 0.1) 0.0 (0.0 to 0.1) 0.1 (0.0 to 0.2) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 
 
Age 18-24 0.2 (0.1 to 0.6) 0.7 (0.5 to 1.1) 0.5 (0.4 to 0.8) 1.2 (0.5 to 2.5) 1.4 (1.0 to 1.9) 1.3 (1.0 to 1.8) 
 
Age 25-44 1.8 (1.5 to 2.1) 2.1 (1.8 to 2.5) 2.0 (1.7 to 2.2) 5.6 (3.7 to 8.2) 3.7 (2.8 to 4.8) 4.1 (3.3 to 5.2) 
 
Age 45-64 3.6 (3.1 to 4.1) 2.2 (1.9 to 2.6) 2.8 (2.6 to 3.2) 4.2 (2.1 to 8.4) 5.3 (3.6 to 7.7) 5.0 (3.5 to 7.0) 
 
Age 65+ 5.2 (4.1 to 6.5) 3.2 (2.4 to 4.3) 4.2 (3.5 to 5.0) 13.6 (4.7 to 33.3) 5.1 (1.7 to 13.9) 7.4 (3.4 to 15.2) 
 
All ages 2.1 (1.9 to 2.4) 1.6 (1.4 to 1.7) 1.8 (1.7 to 2.0) 0.9 (0.6 to 1.2) 0.5 (0.4 to 0.6) 0.6 (0.5 to 0.7) 
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BNF Group / sub group 
and Age group  
Learning disabilities   Autism without learning disabilities 
Female Male Persons Female Male Persons 
4.8 All Antiepileptic drugs 
  
  
   
 
Age <18 11.5 (10.3 to 12.8) 9.5 (8.7 to 10.4) 10.2 (9.5 to 10.9) 3.4 (2.9 to 4.0) 1.7 (1.5 to 1.9) 2.0 (1.8 to 2.2) 
 
Age 18-24 20.4 (18.7 to 22.2) 16.1 (14.9 to 17.4) 17.7 (16.7 to 18.8) 8.8 (6.6 to 11.5) 4.3 (3.6 to 5.2) 5.1 (4.4 to 6.0) 
 
Age 25-44 21.6 (20.6 to 22.7) 23.3 (22.4 to 24.3) 22.6 (21.9 to 23.3) 12.6 (9.8 to 16.2) 6.2 (5.0 to 7.6) 7.7 (6.5 to 9.0) 
 
Age 45-64 25.8 (24.6 to 27.0) 25.9 (24.8 to 27.0) 25.9 (25.1 to 26.7) 12.0 (7.9 to 17.9) 11.2 (8.6 to 14.4) 11.4 (9.1 to 14.2) 
 
Age 65+ 24.5 (22.3 to 26.8) 21.2 (19.1 to 23.4) 22.8 (21.3 to 24.4) 0.0 (0.0 to 14.9) 23.7 (14.7 to 36.0) 17.3 (10.6 to 26.9) 
 
All ages 21.5 (20.9 to 22.1) 20.0 (19.5 to 20.5) 20.6 (20.3 to 21.0) 5.0 (4.4 to 5.7) 2.6 (2.3 to 2.8) 3.0 (2.8 to 3.2) 
4.8.1 Control of the 
epilepsies 
  
  
   
 
Age <18 11.2 (10.1 to 12.5) 9.1 (8.3 to 10.0) 9.9 (9.2 to 10.6) 3.3 (2.7 to 3.9) 1.7 (1.5 to 1.9) 2.0 (1.8 to 2.2) 
 
Age 18-24 19.8 (18.1 to 21.6) 15.5 (14.4 to 16.8) 17.1 (16.2 to 18.1) 8.4 (6.3 to 11.1) 4.1 (3.4 to 5.0) 4.9 (4.1 to 5.7) 
 
Age 25-44 20.2 (19.3 to 21.2) 22.1 (21.2 to 23.0) 21.3 (20.6 to 21.9) 10.0 (7.4 to 13.2) 4.6 (3.6 to 5.8) 5.8 (4.8 to 7.0) 
 
Age 45-64 24.0 (22.9 to 25.2) 24.7 (23.6 to 25.8) 24.4 (23.6 to 25.2) 11.4 (7.5 to 17.2) 9.2 (6.9 to 12.2) 9.8 (7.7 to 12.4) 
 
Age 65+ 22.6 (20.5 to 24.9) 18.8 (16.9 to 21.0) 20.7 (19.2 to 22.3) 0.0 (0.0 to 14.9) 22.0 (13.4 to 34.1) 16.0 (9.6 to 25.5) 
 
All ages 20.2 (19.6 to 20.8) 19.0 (18.5 to 19.5) 19.5 (19.1 to 19.9) 4.6 (4.1 to 5.2) 2.3 (2.1 to 2.5) 2.8 (2.6 to 3.0) 
4.8.2 Drugs used in status 
epilepticus 
  
  
   
 
Age <18 1.7 (1.2 to 2.3) 1.4 (1.1 to 1.8) 1.5 (1.3 to 1.8) 0.4 (0.2 to 0.6) 0.1 (0.1 to 0.2) 0.2 (0.1 to 0.3) 
 
Age 18-24 2.9 (2.3 to 3.8) 2.3 (1.8 to 2.8) 2.5 (2.1 to 3.0) 1.0 (0.4 to 2.3) 0.5 (0.3 to 0.8) 0.5 (0.3 to 0.9) 
 
Age 25-44 4.4 (3.9 to 4.9) 4.0 (3.6 to 4.4) 4.2 (3.9 to 4.5) 3.9 (2.4 to 6.2) 2.5 (1.8 to 3.5) 2.8 (2.2 to 3.7) 
 
Age 45-64 6.5 (5.9 to 7.2) 7.1 (6.5 to 7.8) 6.8 (6.4 to 7.3) 4.2 (2.1 to 8.4) 3.5 (2.2 to 5.6) 3.7 (2.5 to 5.5) 
 
Age 65+ 8.7 (7.3 to 10.3) 6.9 (5.7 to 8.3) 7.8 (6.8 to 8.8) 0.0 (0.0 to 14.9) 1.7 (0.3 to 9.0) 1.2 (0.2 to 6.7) 
 
All ages 4.8 (4.5 to 5.1) 4.2 (3.9 to 4.4) 4.4 (4.3 to 4.7) 0.9 (0.6 to 1.2) 0.4 (0.3 to 0.5) 0.5 (0.4 to 0.6) 
4.8.3 Febrile convulsions 
  
  
   
 
Age <18 0.1 (0.0 to 0.3) 0.1 (0.1 to 0.3) 0.1 (0.1 to 0.2) 0.1 (0.0 to 0.2) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.1) 
 
Age 18-24 0.9 (0.5 to 1.4) 0.9 (0.6 to 1.3) 0.9 (0.7 to 1.2) 0.8 (0.3 to 2.0) 0.4 (0.2 to 0.7) 0.4 (0.3 to 0.8) 
 
Age 25-44 1.5 (1.2 to 1.8) 1.8 (1.6 to 2.2) 1.7 (1.5 to 1.9) 2.9 (1.7 to 5.0) 2.4 (1.7 to 3.4) 2.5 (1.9 to 3.4) 
 
Age 45-64 3.1 (2.7 to 3.7) 2.2 (1.8 to 2.6) 2.6 (2.3 to 2.9) 2.4 (0.9 to 6.0) 1.5 (0.7 to 3.1) 1.8 (1.0 to 3.1) 
 
Age 65+ 3.2 (2.4 to 4.3) 3.0 (2.2 to 4.0) 3.1 (2.5 to 3.8) 0.0 (0.0 to 14.9) 1.7 (0.3 to 9.0) 1.2 (0.2 to 6.7) 
 
All ages 1.9 (1.7 to 2.1) 1.5 (1.4 to 1.7) 1.7 (1.5 to 1.8) 0.5 (0.3 to 0.7) 0.2 (0.2 to 0.3) 0.3 (0.2 to 0.4) 
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Annex table 2. Prescribing patterns for groups and sub-groups of drugs 
BNF section and age group 
Ongoing prescribing 
 
Multiple drugs in group 
Learning disabilities Autism All LD autism 
4.1. All Hypnotics and anxiolytics 
    
 
Age <18 94.0 (91.0 to 96.1) 94.8 (92.8 to 96.2) 8.0 (5.6 to 11.4) 3.5 (2.4 to 5.2) 
 
Age 18-24 90.5 (85.6 to 93.8) 84.1 (73.2 to 91.1) 11.6 (7.8 to 16.7) 11.1 (5.5 to 21.2) 
 
Age 25-44 90.2 (88.0 to 92.1) 88.2 (79.7 to 93.5) 8.4 (6.7 to 10.5) 15.3 (9.2 to 24.4) 
 
Age 45-64 93.1 (91.3 to 94.5) 92.1 (79.2 to 97.3) 11.8 (9.9 to 14.0) 23.7 (13.0 to 39.2) 
 
Age 65+ 94.6 (90.9 to 96.8) 100.0 (61.0 to 100.0) 2.9 (1.4 to 5.9) 0.0 (0.0 to 39.0) 
 All ages 92.2 (91.1 to 93.2) 93.3 (91.5 to 94.8) 9.3 (8.3 to 10.5) 6.0 (4.6 to 7.8) 
4.1.1. Hypnotics 
    
 
Age <18 95.7 (92.8 to 97.5) 95.4 (93.5 to 96.7) 7.3 (4.9 to 10.8) 3.2 (2.1 to 4.8) 
 
Age 18-24 96.3 (90.9 to 98.6) 88.9 (76.5 to 95.2) 5.6 (2.6 to 11.6) 6.7 (2.3 to 17.9) 
 
Age 25-44 94.9 (91.9 to 96.8) 90.7 (78.4 to 96.3) 4.2 (2.4 to 7.0) 0.0 (0.0 to 8.2) 
 
Age 45-64 96.8 (94.6 to 98.1) 95.5 (78.2 to 99.2) 2.2 (1.2 to 4.2) 18.2 (7.3 to 38.5) 
 
Age 65+ 96.9 (91.4 to 99.0) 80.0 (37.6 to 96.4) 0.0 (0.0 to 3.8) 0.0 (0.0 to 43.4) 
 All ages 96.0 (94.8 to 97.0) 94.7 (92.9 to 96.0) 4.1 (3.1 to 5.3) 3.6 (2.5 to 5.1) 
4.1.2. Anxiolytics 
    
 
Age <18 80.4 (66.8 to 89.3) 72.2 (49.1 to 87.5) 0.0 (0.0 to 7.7) 5.6 (1.0 to 25.8) 
 
Age 18-24 85.0 (76.7 to 90.7) 76.2 (54.9 to 89.4) 13.0 (7.8 to 21.0) 0.0 (0.0 to 15.5) 
 
Age 25-44 87.1 (84.0 to 89.6) 88.9 (77.8 to 94.8) 5.6 (3.9 to 7.8) 13.0 (6.4 to 24.4) 
 
Age 45-64 90.2 (87.6 to 92.3) 89.5 (68.6 to 97.1) 8.2 (6.3 to 10.6) 10.5 (2.9 to 31.4) 
 
Age 65+ 92.5 (87.1 to 95.8) 100.0 (34.2 to 100.0) 1.4 (0.4 to 4.8) 0.0 (0.0 to 65.8) 
 All ages 88.6 (86.9 to 90.1) 84.2 (76.4 to 89.8) 6.6 (5.4 to 8.0) 8.8 (4.8 to 15.4) 
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BNF section and age group 
Ongoing prescribing 
 
Multiple drugs in group 
Learning disabilities Autism All LD autism 
4.2. All Antipsychotics 
    
 
Age <18 94.3 (90.1 to 96.8) 95.5 (92.8 to 97.3) 9.8 (6.4 to 14.9) 8.0 (5.6 to 11.4) 
 
Age 18-24 99.1 (97.9 to 99.6) 98.4 (95.4 to 99.5) 21.3 (18.1 to 25.0) 20.9 (15.6 to 27.2) 
 
Age 25-44 99.3 (98.8 to 99.5) 97.6 (94.5 to 99.0) 28.2 (26.5 to 30.0) 18.6 (13.9 to 24.4) 
 
Age 45-64 99.5 (99.2 to 99.7) 98.9 (93.9 to 99.8) 28.6 (27.0 to 30.3) 24.7 (16.9 to 34.6) 
 
Age 65+ 99.5 (98.7 to 99.8) 100.0 (64.6 to 100.0) 21.1 (18.4 to 24.1) 14.3 (2.6 to 51.3) 
 All ages 99.3 (99.0 to 99.4) 97.1 (95.7 to 98.0) 26.5 (25.5 to 27.6) 15.4 (13.1 to 18.1) 
4.2.1. Antipsychotic drugs 
    
 
Age <18 95.9 (91.8 to 98.0) 95.5 (92.6 to 97.3) 7.0 (4.0 to 11.8) 8.3 (5.8 to 11.9) 
 
Age 18-24 98.4 (96.8 to 99.2) 97.5 (93.6 to 99.0) 15.7 (12.6 to 19.4) 17.2 (12.1 to 23.9) 
 
Age 25-44 99.2 (98.7 to 99.5) 98.0 (94.9 to 99.2) 24.3 (22.5 to 26.2) 13.6 (9.5 to 19.0) 
 
Age 45-64 99.5 (99.2 to 99.7) 97.4 (91.0 to 99.3) 24.0 (22.3 to 25.7) 20.8 (13.2 to 31.1) 
 
Age 65+ 99.5 (98.6 to 99.8) 100.0 (64.6 to 100.0) 16.8 (14.3 to 19.6) 14.3 (2.6 to 51.3) 
 All ages 99.2 (99.0 to 99.4) 96.8 (95.3 to 97.8) 22.1 (21.0 to 23.1) 12.9 (10.7 to 15.5) 
4.2.2. Antipsychotic depot injections 
    
 
Age <18 - - - - 
 
Age 18-24 - - - - 
 
Age 25-44 90.5 (71.1 to 97.3) 100.0 (34.2 to 100.0) 0.0 (0.0 to 15.5) 0.0 (0.0 to 65.8) 
 
Age 45-64 95.0 (83.5 to 98.6) - 7.5 (2.6 to 19.9) - 
 
Age 65+ 100.0 (86.7 to 100.0) - 12.0 (4.2 to 30.0) - 
 All ages 95.3 (88.6 to 98.2) 100.0 (34.2 to 100.0) 7.0 (3.2 to 14.4) 0.0 (0.0 to 65.8) 
4.2.3. Drugs used for mania and 
hypomania 
    
 
Age <18 100.0 (83.9 to 100.0) 97.2 (85.8 to 99.5) 35.0 (18.1 to 56.7) 8.3 (2.9 to 21.8) 
 
Age 18-24 99.4 (96.8 to 99.9) 98.4 (91.5 to 99.7) 26.6 (20.6 to 33.6) 19.0 (11.2 to 30.4) 
 
Age 25-44 99.7 (99.1 to 99.9) 98.7 (93.1 to 99.8) 23.4 (20.9 to 26.2) 12.8 (7.1 to 22.0) 
 
Age 45-64 99.7 (99.2 to 99.9) 97.9 (88.9 to 99.6) 24.6 (22.1 to 27.3) 23.4 (13.6 to 37.2) 
 
Age 65+ 99.5 (97.4 to 99.9) - 20.3 (15.5 to 26.1) - 
 All ages 99.7 (99.3 to 99.8) 98.2 (95.5 to 99.3) 24.0 (22.3 to 25.7) 16.1 (11.8 to 21.4) 
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BNF section and age group 
Ongoing prescribing 
 
Multiple drugs in group 
Learning disabilities Autism All LD autism 
4.3. All Antidepressants 
    
 
Age <18 98.9 (93.8 to 99.8) 96.7 (93.7 to 98.3) 5.7 (2.5 to 12.6) 3.7 (2.0 to 6.9) 
 
Age 18-24 98.0 (96.2 to 98.9) 96.4 (93.5 to 98.0) 9.3 (6.9 to 12.3) 8.6 (5.9 to 12.5) 
 
Age 25-44 98.7 (98.2 to 99.1) 98.2 (96.4 to 99.1) 10.3 (9.1 to 11.6) 9.4 (7.0 to 12.5) 
 
Age 45-64 99.3 (98.9 to 99.6) 98.9 (96.1 to 99.7) 11.7 (10.5 to 13.1) 14.6 (10.2 to 20.4) 
 
Age 65+ 99.7 (98.8 to 99.9) 100.0 (83.9 to 100.0) 9.7 (7.6 to 12.4) 15.0 (5.2 to 36.0) 
 All ages 99.0 (98.7 to 99.2) 97.6 (96.5 to 98.3) 10.7 (9.9 to 11.5) 9.0 (7.4 to 10.7) 
4.3.1. Tricyclic and related 
antidepressant drugs 
    
 
Age <18 100.0 (61.0 to 100.0) 90.9 (72.2 to 97.5) 33.3 (9.7 to 70.0) 0.0 (0.0 to 14.9) 
 
Age 18-24 95.9 (86.3 to 98.9) 96.3 (81.7 to 99.3) 2.0 (0.4 to 10.7) 11.1 (3.9 to 28.1) 
 
Age 25-44 96.9 (94.6 to 98.3) 95.1 (86.5 to 98.3) 8.7 (6.2 to 12.0) 1.6 (0.3 to 8.7) 
 
Age 45-64 98.0 (96.4 to 98.9) 97.6 (87.4 to 99.6) 9.6 (7.3 to 12.5) 7.3 (2.5 to 19.4) 
 
Age 65+ 100.0 (97.9 to 100.0) 100.0 (20.7 to 100.0) 4.4 (2.2 to 8.4) 0.0 (0.0 to 79.3) 
 All ages 97.9 (96.9 to 98.6) 95.4 (90.8 to 97.8) 8.2 (6.7 to 10.0) 4.6 (2.2 to 9.2) 
4.3.3. Selective serotonin re-uptake 
inhibitors 
    
 
Age <18 97.5 (91.3 to 99.3) 97.3 (94.2 to 98.8) 3.8 (1.3 to 10.5) 3.6 (1.8 to 6.9) 
 
Age 18-24 98.0 (96.0 to 99.0) 96.7 (93.4 to 98.4) 7.9 (5.5 to 11.1) 5.1 (2.9 to 9.0) 
 
Age 25-44 98.7 (98.0 to 99.2) 98.1 (95.8 to 99.1) 6.4 (5.3 to 7.7) 7.8 (5.3 to 11.3) 
 
Age 45-64 99.5 (99.0 to 99.7) 99.2 (95.7 to 99.9) 7.8 (6.6 to 9.2) 11.6 (7.2 to 18.3) 
 
Age 65+ 99.7 (98.3 to 99.9) 93.8 (71.7 to 98.9) 6.4 (4.2 to 9.5) 18.8 (6.6 to 43.0) 
 All ages 99.0 (98.7 to 99.3) 97.6 (96.4 to 98.5) 7.0 (6.3 to 7.9) 6.9 (5.4 to 8.7) 
4.3.4. Other antidepressant drugs 
    
 
Age <18 100.0 (20.7 to 100.0) 100.0 (51.0 to 100.0) 0.0 (0.0 to 79.3) 0.0 (0.0 to 49.0) 
 
Age 18-24 96.7 (83.3 to 99.4) 94.9 (83.1 to 98.6) 0.0 (0.0 to 11.4) 15.4 (7.2 to 29.7) 
 
Age 25-44 98.2 (95.9 to 99.2) 98.6 (92.6 to 99.8) 11.9 (8.6 to 16.2) 16.4 (9.7 to 26.6) 
 
Age 45-64 99.4 (97.8 to 99.8) 96.8 (83.8 to 99.4) 13.9 (10.5 to 18.1) 9.7 (3.3 to 24.9) 
 
Age 65+ 100.0 (96.8 to 100.0) 100.0 (61.0 to 100.0) 4.3 (1.9 to 9.8) 0.0 (0.0 to 39.0) 
 All ages 98.9 (97.9 to 99.5) 97.4 (93.5 to 99.0) 11.1 (9.0 to 13.5) 13.7 (9.2 to 20.1) 
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BNF section and age group 
Ongoing prescribing 
 
Multiple drugs in group 
Learning disabilities Autism All LD autism 
4.8 All Antiepileptic drugs 
    
 
Age <18 98.8 (97.7 to 99.4) 98.1 (96.4 to 99.1) 27.9 (24.8 to 31.2) 27.3 (23.3 to 31.7) 
 
Age 18-24 98.9 (98.0 to 99.4) 97.3 (93.3 to 99.0) 38.0 (35.0 to 41.1) 32.2 (25.2 to 40.1) 
 
Age 25-44 99.1 (98.7 to 99.4) 97.1 (92.7 to 98.9) 42.5 (40.8 to 44.3) 33.8 (26.4 to 42.1) 
 
Age 45-64 99.3 (98.9 to 99.5) 97.2 (90.3 to 99.2) 46.8 (45.0 to 48.6) 25.4 (16.7 to 36.6) 
 
Age 65+ 99.4 (98.4 to 99.8) 92.9 (68.5 to 98.7) 39.4 (35.6 to 43.2) 28.6 (11.7 to 54.6) 
 All ages 99.1 (98.9 to 99.3) 97.6 (96.3 to 98.5) 42.0 (40.9 to 43.0) 29.2 (26.1 to 32.4) 
4.8.1 Control of the epilepsies 
    
 
Age <18 99.4 (98.6 to 99.8) 98.8 (97.2 to 99.5) 25.2 (22.1 to 28.5) 24.5 (20.6 to 28.8) 
 
Age 18-24 99.4 (98.6 to 99.7) 99.3 (96.1 to 99.9) 37.1 (34.1 to 40.3) 32.4 (25.2 to 40.5) 
 
Age 25-44 99.7 (99.5 to 99.9) 99.0 (94.7 to 99.8) 43.8 (42.0 to 45.6) 38.8 (30.0 to 48.5) 
 
Age 45-64 99.8 (99.6 to 99.9) 96.7 (88.8 to 99.1) 46.3 (44.5 to 48.2) 29.5 (19.6 to 41.9) 
 
Age 65+ 99.8 (99.0 to 100.0) 100.0 (77.2 to 100.0) 40.4 (36.4 to 44.5) 30.8 (12.7 to 57.6) 
 All ages 99.7 (99.6 to 99.8) 98.8 (97.7 to 99.4) 42.0 (40.9 to 43.1) 28.5 (25.4 to 31.9) 
4.8.2 Drugs used in status 
epilepticus 
    
 
Age <18 77.3 (68.6 to 84.1) 67.5 (52.0 to 79.9) 6.4 (3.1 to 12.6) 5.0 (1.4 to 16.5) 
 
Age 18-24 83.6 (76.6 to 88.8) 75.0 (50.5 to 89.8) 11.4 (7.2 to 17.8) 0.0 (0.0 to 19.4) 
 
Age 25-44 90.0 (87.3 to 92.2) 90.0 (78.6 to 95.7) 10.7 (8.4 to 13.4) 2.0 (0.4 to 10.5) 
 
Age 45-64 94.3 (92.5 to 95.7) 87.0 (67.9 to 95.5) 20.0 (17.4 to 23.0) 13.0 (4.5 to 32.1) 
 
Age 65+ 95.8 (92.2 to 97.8) 100.0 (20.7 to 100.0) 17.7 (13.2 to 23.3) 0.0 (0.0 to 79.3) 
 All ages 91.3 (89.9 to 92.5) 80.8 (73.2 to 86.6) 15.3 (13.7 to 17.0) 4.6 (2.1 to 9.7) 
4.8.3 Febrile convulsions 
    
 
Age <18 75.0 (40.9 to 92.9) 60.0 (23.1 to 88.2) 0.0 (0.0 to 32.4) 0.0 (0.0 to 43.4) 
 
Age 18-24 87.8 (75.8 to 94.3) 76.9 (49.7 to 91.8) 14.3 (7.1 to 26.7) 0.0 (0.0 to 22.8) 
 
Age 25-44 86.7 (81.8 to 90.4) 88.9 (76.5 to 95.2) 4.6 (2.6 to 8.0) 2.2 (0.4 to 11.6) 
 
Age 45-64 91.0 (87.2 to 93.7) 81.8 (52.3 to 94.9) 8.7 (6.0 to 12.4) 0.0 (0.0 to 25.9) 
 
Age 65+ 95.3 (88.6 to 98.2) 100.0 (20.7 to 100.0) 0.0 (0.0 to 4.3) 0.0 (0.0 to 79.3) 
 
All ages 89.6 (87.1 to 91.7) 84.0 (74.1 to 90.6) 6.5 (4.8 to 8.6) 1.3 (0.2 to 7.2) 
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Annex table 3. Variation in rate of exposure of whole patient group to drugs from BNF sections/sub-sections across the three years studied 
Drug group / sub-group 2009/2010 2010/2011 2011/2012 
4.1. All Hypnotics and anxiolytics 4.9 (4.7 to 5.2) 5.1 (4.8 to 5.4) 5.3 (5.0 to 5.6) 
4.1.1. Hypnotics 2.8 (2.6 to 3.1) 3.0 (2.8 to 3.2) 3.2 (2.9 to 3.4) 
4.1.2. Anxiolytics 2.4 (2.2 to 2.6) 2.3 (2.2 to 2.6) 2.3 (2.1 to 2.5) 
4.2. All Antipsychotics 11.2 (10.7 to 11.6) 11.3 (10.9 to 11.7) 11.5 (11.1 to 12.0) 
4.2.1. Antipsychotic drugs 9.7 (9.3 to 10.1) 9.8 (9.4 to 10.2) 10.0 (9.6 to 10.5) 
4.2.2. Antipsychotic depot injections 0.1 (0.1 to 0.2) 0.1 (0.1 to 0.2) 0.1 (0.1 to 0.2) 
4.2.3. Drugs used for mania and hypomania 3.8 (3.5 to 4.1) 4.0 (3.7 to 4.2) 4.0 (3.7 to 4.2) 
4.3. All Antidepressants 9.6 (9.2 to 10.1) 10.3 (9.9 to 10.7) 10.9 (10.5 to 11.4) 
4.3.1. Tricyclic and related antidepressant drugs 1.8 (1.7 to 2.0) 1.8 (1.7 to 2.0) 1.9 (1.7 to 2.1) 
4.3.3. Selective serotonin re-uptake inhibitors 6.8 (6.4 to 7.1) 7.3 (6.9 to 7.6) 7.8 (7.4 to 8.1) 
4.3.4. Other antidepressant drugs 1.2 (1.0 to 1.3) 1.3 (1.2 to 1.5) 1.5 (1.4 to 1.7) 
4.8 All Antiepileptic drugs 12.1 (11.7 to 12.6) 12.1 (11.6 to 12.6) 12.1 (11.6 to 12.5) 
4.8.1 Control of the epilepsies 12.9 (12.4 to 13.3) 12.9 (12.5 to 13.4) 13.0 (12.5 to 13.4) 
4.8.2 Drugs used in status epilepticus 3.0 (2.8 to 3.2) 2.9 (2.7 to 3.2) 2.7 (2.5 to 3.0) 
4.8.3 Febrile convulsions 1.1 (1.0 to 1.3) 1.1 (1.0 to 1.3) 1.1 (0.9 to 1.2) 
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Annex table 4. Prescribing episode patterns. The table shows the proportions of days in prescribing episodes in which the patient was in an 
‘ongoing’ prescribing episode or receiving more than one agent in the drug class or sub-class concerned   
  Proportion ongoing Proportion Multiple 
  Learning disabilities Autism without learning disabilities Learning disabilities Autism without learning disabilities 
  Under 18 18 and older Under 18 18 and older Under 18 18 and older Under 18 18 and older 
4.1. All Hypnotics and 
anxiolytics 94.0 91.9 94.8 88.0 8.0 9.5 3.5 15.1 
  (91.0 to 96.1) (90.7 to 93.0) (92.8 to 96.2) (82.7 to 91.9) (5.6 to 11.4) (8.4 to 10.8) (2.4 to 5.2) (10.7 to 20.9) 
4.1.1. Hypnotics 95.7 96.1 95.4 90.4 7.3 3.0 3.2 6.1 
  (92.8 to 97.5) (94.7 to 97.2) (93.5 to 96.7) (83.7 to 94.6) (4.9 to 10.8) (2.1 to 4.3) (2.1 to 4.8) (3.0 to 12.0) 
4.1.2. Anxiolytics 80.4 88.9 72.2 86.5 0.0 6.8 5.6 9.4 
  (66.8 to 89.3) (87.1 to 90.4) (49.1 to 87.5) (78.2 to 91.9) (0.0 to 7.7) (5.6 to 8.2) (1.0 to 25.8) (5.0 to 16.9) 
4.2. All Antipsychotics 94.3 99.4 95.5 98.2 9.8 27.0 8.0 20.5 
  (90.1 to 96.8) (99.2 to 99.6) (92.8 to 97.3) (96.6 to 99.0) (6.4 to 14.9) (25.9 to 28.1) (5.6 to 11.4) (17.2 to 24.3) 
4.2.1. Antipsychotic drugs 95.9 99.3 95.5 97.7 7.0 22.5 8.3 16.1 
  (91.8 to 98.0) (99.1 to 99.5) (92.6 to 97.3) (95.9 to 98.8) (4.0 to 11.8) (21.5 to 23.6) (5.8 to 11.9) (13.0 to 19.9) 
4.2.2. Antipsychotic depot 
injections 
- 95.3 - 100.0 - 7.0 - 0.0 
 
(88.6 to 98.2) 
 
(34.2 to 100.0) 
 
(3.2 to 14.4) 
 
(0.0 to 65.8) 
4.2.3. Drugs used for mania 
and hypomania 
100.0 99.7 97.2 98.4 35.0 23.9 8.3 17.6 
(83.9 to 100.0) (99.3 to 99.8) (85.8 to 99.5) (95.4 to 99.5) (18.1 to 56.7) (22.2 to 25.6) (2.9 to 21.8) (12.8 to 23.6) 
4.3. All Antidepressants 98.9 99.0 96.7 97.8 5.7 10.8 3.7 10.3 
  (93.8 to 99.8) (98.7 to 99.2) (93.7 to 98.3) (96.7 to 98.6) (2.5 to 12.6) (10.0 to 11.6) (2.0 to 6.9) (8.5 to 12.5) 
4.3.1. Tricyclic and related 
antidepressant drugs 
100.0 97.9 90.9 96.2 33.3 8.1 0.0 5.4 
(61.0 to 100.0) (96.9 to 98.6) (72.2 to 97.5) (91.3 to 98.3) (9.7 to 70.0) (6.6 to 9.9) (0.0 to 14.9) (2.6 to 10.7) 
4.3.3. Selective serotonin re-
uptake inhibitors 
97.5 99.0 97.3 97.8 3.8 7.1 3.6 7.9 
(91.3 to 99.3) (98.7 to 99.3) (94.2 to 98.8) (96.3 to 98.6) (1.3 to 10.5) (6.3 to 7.9) (1.8 to 6.9) (6.1 to 10.2) 
4.3.4. Other antidepressant 
drugs 
100.0 98.9 100.0 97.3 0.0 11.1 0.0 14.1 
(20.7 to 100.0) (97.9 to 99.5) (51.0 to 100.0) (93.3 to 99.0) (0.0 to 79.3) (9.1 to 13.6) (0.0 to 49.0) (9.4 to 20.6) 
4.8 All Antiepileptic drugs 98.8 99.2  98.1  97.0 27.9 43.3 27.3 31.4 
  (97.7 to 99.4)  (98.9 to 99.4)  (96.4 to 99.1)  (94.8 to 98.3) (24.8 to 31.2) (42.2 to 44.4) (23.3 to 31.7) (26.8 to 36.2) 
4.8.1 Control of the epilepsies 99.4 99.7 98.8 98.7 25.2 43.6 24.5 33.9 
  (98.6 to 99.8) (99.6 to 99.8) (97.2 to 99.5) (96.8 to 99.5) (22.1 to 28.5) (42.5 to 44.8) (20.6 to 28.8) (28.9 to 39.2) 
4.8.2 Drugs used in status 
epilepticus 
77.3 92.1 67.5 86.7 6.4 15.8 5.0 4.4 
(68.6 to 84.1) (90.8 to 93.3) (52.0 to 79.9) (78.1 to 92.2) (3.1 to 12.6) (14.2 to 17.6) (1.4 to 16.5) (1.7 to 10.9) 
4.8.3 Febrile convulsions 75.0 89.8 60.0 85.7 0.0 6.5 0.0 1.4 
  (40.9 to 92.9) (87.2 to 91.8) (23.1 to 88.2) (75.7 to 92.1) (0.0 to 32.4) (4.9 to 8.7) (0.0 to 43.4) (0.3 to 7.7) 
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Annex table 5. Proportion (%) of prescriptions for drugs where dose was not identifiable (20150412) 
  People with learning disabilities People with autism but not learning disabilities 
BNF Sub group Under 18 18 and older Under 18 18 and older 
4.1. All Hypnotics and anxiolytics 53.0 (51.5 to 54.5) 41.2 (40.7 to 41.6) 39.7 (38.6 to 40.8) 32.8 (31.2 to 34.4) 
4.1.1. Hypnotics 50.6 (49.0 to 52.2) 20.8 (20.2 to 21.4) 39.0 (37.9 to 40.1) 12.8 (11.3 to 14.4) 
4.1.2. Anxiolytics 67.1 (63.3 to 70.7) 55.0 (54.3 to 55.6) 55.1 (49.6 to 60.5) 55.8 (53.3 to 58.3) 
4.2. All Antipsychotics 52.7 (50.7 to 54.7) 25.8 (25.6 to 26.0) 40.3 (38.8 to 41.7) 20.9 (20.1 to 21.8) 
4.2.1. Antipsychotic drugs 56.6 (54.5 to 58.7) 25.2 (24.9 to 25.4) 41.5 (40.0 to 43.1) 21.9 (20.9 to 22.9) 
4.2.2. Antipsychotic depot injections - 77.4 (75.0 to 79.7) - 100.0 (80.6 to 100.0) 
4.2.3. Drugs used for mania and hypomania 19.6 (15.3 to 24.8) 22.5 (22.2 to 22.9) 27.0 (23.8 to 30.4) 13.6 (12.5 to 14.8) 
4.3. All Antidepressants 33.7 (31.1 to 36.5) 16.5 (16.3 to 16.8) 29.8 (28.2 to 31.4) 13.4 (12.8 to 14.0) 
4.3.1. Tricyclic and related antidepressant drugs 31.6 (22.2 to 42.7) 20.3 (19.7 to 20.8) 21.4 (16.6 to 27.2) 25.4 (23.4 to 27.5) 
4.3.3. Selective serotonin re-uptake inhibitors 31.0 (28.2 to 33.9) 15.0 (14.7 to 15.3) 29.9 (28.2 to 31.7) 11.1 (10.5 to 11.8) 
4.3.4. Other antidepressant drugs 78.6 (52.4 to 92.4) 15.9 (15.3 to 16.4) 15.0 (9.3 to 23.3) 11.8 (10.5 to 13.2) 
4.8 All Antiepileptic drugs 51.4 (50.6 to 52.2) 29.4 (29.3 to 29.6) 48.7 (47.6 to 49.8) 30.2 (29.2 to 31.2) 
4.8.1 Control of the epilepsies 48.1 (47.3 to 49.0) 27.2 (27.0 to 27.3) 46.2 (45.1 to 47.3) 25.4 (24.4 to 26.4) 
4.8.2 Drugs used in status epilepticus 84.2 (82.1 to 86.1) 43.9 (43.4 to 44.5) 83.6 (80.2 to 86.5) 54.4 (51.6 to 57.1) 
4.8.3 Febrile convulsions 50.9 (41.6 to 60.2) 46.2 (45.3 to 47.1) 35.8 (27.4 to 45.1) 55.8 (52.9 to 58.7) 
All 50.9 (50.2 to 51.5) 26.1 (26.0 to 26.2) 41.5 (40.8 to 42.1) 20.2 (19.8 to 20.7) 
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Annex table 6. Proportion (%) of prescriptions for drugs where dose specified exceeded BNF recommended maximum for BNF sections and sub-
sections. Note this table should be read in conjunction with the preceding table which indicates the proportion of cases were doses were 
known(20150412) 
  People with learning disabilities 
People with autism but not learning 
disabilities 
BNF Sub group Under 18 18 and older Under 18 18 and older 
4.1. All Hypnotics and anxiolytics 0.3 (0.1 to 0.5) 2.4 (2.3 to 2.6) 0.4 (0.3 to 0.6) 1.4 (1.0 to 1.8) 
4.1.1. Hypnotics 0.2 (0.1 to 0.4) 2.4 (2.2 to 2.7) 0.4 (0.3 to 0.5) 1.7 (1.2 to 2.4) 
4.1.2. Anxiolytics 0.7 (0.3 to 1.7) 2.4 (2.2 to 2.6) 1.0 (0.3 to 2.8) 1.0 (0.6 to 1.7) 
4.2. All Antipsychotics 1.3 (0.9 to 1.9) 4.5 (4.4 to 4.6) 1.2 (0.9 to 1.5) 4.7 (4.3 to 5.2) 
4.2.1. Antipsychotic drugs 1.5 (1.0 to 2.1) 5.5 (5.4 to 5.7) 1.3 (1.0 to 1.7) 5.6 (5.1 to 6.2) 
4.2.2. Antipsychotic depot injections - 0.0 (0.0 to 0.3) - 0.0 (0.0 to 19.4) 
4.2.3. Drugs used for mania and hypomania 0.0 (0.0 to 1.4) 0.3 (0.3 to 0.3) 0.0 (0.0 to 0.5) 0.1 (0.0 to 0.2) 
4.3. All Antidepressants 0.0 (0.0 to 0.3) 0.6 (0.5 to 0.6) 0.7 (0.4 to 1.0) 1.1 (0.9 to 1.3) 
4.3.1. Tricyclic and related antidepressant drugs 0.0 (0.0 to 4.8) 1.9 (1.7 to 2.1) 8.7 (5.7 to 13.1) 4.6 (3.7 to 5.7) 
4.3.3. Selective serotonin re-uptake inhibitors 0.0 (0.0 to 0.4) 0.2 (0.2 to 0.2) 0.0 (0.0 to 0.1) 0.8 (0.6 to 1.0) 
4.3.4. Other antidepressant drugs 0.0 (0.0 to 21.5) 0.1 (0.0 to 0.1) 0.0 (0.0 to 3.7) 0.0 (0.0 to 0.2) 
4.8 All Antiepileptic drugs 0.8 (0.6 to 0.9) 0.8 (0.8 to 0.9) 0.4 (0.3 to 0.5) 0.2 (0.1 to 0.3) 
4.8.1 Control of the epilepsies 0.8 (0.7 to 1.0) 0.7 (0.7 to 0.7) 0.4 (0.3 to 0.5) 0.2 (0.1 to 0.4) 
4.8.2 Drugs used in status epilepticus 0.2 (0.0 to 0.6) 1.4 (1.3 to 1.5) 0.6 (0.2 to 1.7) 0.0 (0.0 to 0.3) 
4.8.3 Febrile convulsions 1.9 (0.5 to 6.5) 2.6 (2.3 to 2.9) 2.8 (0.9 to 7.8) 0.0 (0.0 to 0.3) 
 
 
 
 
